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Welcome to the Forum! 
We have experienced another wonderful year in the Jefferson Internal Medicine 
Residency Program! Our program continues to attract the best and brightest 
medical students who over three years become outstanding clinicians, 
accomplished researchers and compassionate physicians. Residency training 
is increasingly complex, with competing demands compressing their work into 
fewer hours. I am consistently impressed with the camaraderie among our 
housestaff—they not only take care of patients, but they take care of each other. 
It is something that sets our program apart from others and is something of 
which I am incredibly proud.
Like every year, this year has come with changes. Besides being one of the worst 
winters on record in Philadelphia and having a hospital that was often bursting 
at the seams with patients, the Next Accreditation System from the ACGME was 
implemented. This has shifted the way residency programs are accredited and 
prompted us to overhaul our evaluation system for residents. Our patient safety 
and quality improvement curriculum began this year with great success and the 
housestaff have embraced it. We have already seen results from improvement 
cycles and engagement into systems changes resulting in delivery of better 
care to our patients. Our residents know this hospital inside and out and are in 
a great position to be the leaders we need in quality improvement and patient 
safety at Jefferson.
Our residents have put together yet another outstanding journal showcasing 
their academic interests and humanistic talents. I hope you will enjoy reading it!
Gretchen Diemer, MD, FACP
Assistant Professor of Medicine
Program Director
From the 
Desk oF the
resiDency
Program 
Director
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We are proud to publish the 15th issue of The Medicine Forum. Since its 
inception, this journal has provided a medium for medical students and 
housestaff to share their scholarly pursuits and clinical experiences with the 
Jefferson community. It has served as a platform both for those pursuing 
careers in academic medicine as well as those wishing to share their 
personal experiences with a larger audience. This year we are introducing a 
new section called Clinical Images which will showcase interesting physical 
exam findings and radiographic images accompanied by brief patient 
vignettes. We have been fortunate to have received numerous fascinating 
case reports, review articles, and clinical images, as well as one narrative 
essay for this year’s edition. Additionally, we are very proud to present original 
photography, artwork, and illustrations by Internal Medicine housestaff 
throughout this edition. We appreciate the efforts of all those involved in 
the publication of The Medicine Forum, particularly those individuals who 
have donated funds to allow for this journal’s publication, the editorial staff, 
Jefferson Creative Services, and the Internal Medicine Department.
Harkirat Singh, MD
Michael A. Valentino, MD, PhD 
Executive Editors
From the 
eDitors
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was found to have obstructive jaundice and new 
liver metastases on CT scan. He underwent an ERCP 
procedure with biliary stenting for palliation and was 
discharged home.
Ten days following the procedure, the patient 
presented with complaints of fever to 102oF and 
fatigue. Vital signs revealed a fever of 101.3oF but were 
otherwise unremarkable. Physical examination revealed 
improvement of his jaundice, normal cardiopulmonary 
examination, and right upper quadrant tenderness. 
Despite four days of vancomycin and piperacillin-
tazobactam, the patient continued to be febrile to 
102.5oF. 
DiFFErEnTial DiagnoSiS
The medical team remained concerned about infectious 
etiologies, including cholangitis, bacteremia, and 
endocarditis. Non-infectious causes of his fever were 
inTroDucTion
Achromobacter xylosoxidans is a rare cause of 
bacteremia; however patients with underlying illness, 
especially malignancies, are at increased risk of 
infection. Antibiotic therapy against this pathogen can 
be difficult owing to its inherent resistance to multiple 
common antibiotics.
caSE PrESEnTaTion
A 69-year-old male with adenocarcinoma of 
the colon status post right hemicolectomy and 
chemotherapy presented with fever and fatigue 10 
days following endoscopic retrograde cholangio-
pancreatography (ERCP) with biliary stent placement 
for new liver metastases. The patient had undergone 
partial hemicolectomy and had completed 12 cycles 
of adjuvant FOLFOX (leucovorin, 5-fluorouracil, and 
oxaliplatin) at the time of initial diagnosis. Two years 
following the completion of chemotherapy, the patient 
Sustained Achromobacter Xylosoxidans 
Bacteremia in a Patient with Adenocarcinoma 
of the Colon
Matt Enriquez, MS IV, Andi Favini MS IV, Kevin Curl, MD
Table 1. Antibiotic sensitivities (represented as percent susceptible) of Achromobacter xylosoxidans in several case 
reports and the current patient’s susceptibilities. 
Antibiotic
Turel O, et al.  
(34 isolates)
Glupczynski Y, et al. 
(37 isolates)
Current Patient
Antibiotic
Trimethoprim-Sulfamethoxazole 100 67 Unknown
Meropenem 100 100 Susceptible
Piperacillin-Tazobactam 91 91 Resistant
Ciprofloxacin 82 0 Susceptible
Ceftazidime 82 81 Resistant
Cefepime 15 0 Unknown
Gentamicin 0 0 Intermediate
* Turel O, et al. isolates were from a neonatal intensive care unit in Turkey, while Glupczynski, et al. isolates were from a single hospital in Belgium.
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Common symptoms of A. xylosoxidans bacteremia 
include fever, fatigue, and persistence of symptoms 
despite broad-spectrum antibiotic therapy. A unique 
symptom to this presentation was right upper quadrant 
abdominal pain consistent with a gastrointestinal source 
of infection secondary to the patient’s prior ERCP. Aside 
from gastrointestinal infections, other common sources 
of infection include catheter-associated infections and 
pneumonia.1
As A. xylosoxidans bacteremia is often associated 
with specific predisposing conditions and sources of 
infection, early identification of risk factors for infection 
remains a crucial component of diagnosis. Initial 
diagnostic tests to determine if the bacteremia is due 
to A. xylosoxidans include repeating blood cultures 
which may demonstrate sustained gram-negative 
rod bacteremia. Another useful part of the diagnostic 
work-up includes identifying the original source of 
the patient’s bacteremia in addition to ongoing site of 
infection. In this case, ultrasound served to localize a 
right cephalic vein clot as the probable ongoing site of 
infection; this clot had likely been seeded by a gastroin-
testinal source around the time of the ERCP procedure.
Choosing antibiotic therapy to treat A. xylosoxidans 
bacteremia proves challenging because of its inherent 
resistance to multiple antibiotics in addition to its 
ability to harbor and horizontally transfer resistance 
genes (Table 1). A proposed transfer mechanism for 
A. xylosoxidans has been shown to potentially involve 
integrons, R plasmids, and insertion sequences.2-4
A. xylosoxidans remains an important emerging cause 
of nosocomial and community-acquired infections 
because of its resistance to multiple antibiotics. Although 
individual patterns vary, most strains of A. xylosoxidans 
are resistant to aminoglycosides and quinolones.2 
The majority of isolates have demonstrated suscepti-
bility to tazobactam, imipenem and meropenem, but 
as demonstrated in Table 1, this patient harbored a 
strain that was also resistant to piperacillin-tazobactam. 
Aggressive measures to sterilize hospital solutions and 
equipment, as well as to enforce policies to prevent 
antibiotic misuse, should be employed to prevent future 
cases of Achromobacter xylosoxidans bacteremia and 
to quell the propagation of drug resistance in this 
pathogen.
also considered, such as post-ERCP pancreatitis, deep 
venous thrombosis, and malignancy-related fever.
ouTcoME anD Follow-uP
Routine laboratory studies were unremarkable, 
including serum amylase and lipase. Right upper 
quadrant ultrasound and CT scan of the abdomen 
and pelvis did not show any visible infectious source. 
Transthoracic echocardiogram was not consistent 
with endocarditis. Lower extremity Dopplers were 
negative, and while upper extremity Dopplers revealed 
no deep venous thrombosis, they did show a right 
cephalic vein clot. Blood cultures drawn on admission 
were found to be positive for gram-negative bacilli on 
hospital day three. Subsequent blood cultures drawn 
after the initiation of broad-spectrum antibiotics 
were also positive for gram-negative bacilli. Prior to 
speciation, the Infectious Disease team recommended 
discontinuing vancomycin and switching the 
piperacillin-tazobactam to meropenem. On hospital 
day number seven, the patient became afebrile and 
blood culture speciation revealed Achromobacter 
xylosoxidans with sensitivities listed in Table 1. Blood 
cultures drawn after the adjustment of antibiotic 
therapy to meropenem remained negative. It was 
believed that the patient had a transient bacteremia 
of Achromobacter xylosoxidans related to the ERCP 
that had seeded his cephalic vein thrombus, leading to 
persistent bacteremia. Based on culture sensitivities, the 
patient’s antibiotics were changed to oral ciprofloxacin 
to complete a four week course of antibiotics. He was 
also started on prophylactic enoxaparin for his cephalic 
vein thrombus and was discharged home. 
DiScuSSion
Bacteremia due to A. xylosoxidans remains rare, 
yet patients with underlying illness, particularly 
malignancies, are at increased risk of infection. 
Other predisposing conditions include cardiovascular 
disease, renal failure, and immune suppression.1 
Though A. xylosoxidans is not a typical component 
of endogenous human flora, it is known to inhabit 
aqueous environments with common sources 
including contaminated water and IV fluids, intravenous 
catheters, humidification fluids, and instrumentation 
utilized during surgical interventions.1
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KEy PoinTS
This case serves as a reminder to consider A. 
xylosoxidans when treating patients with underlying 
illnesses, particularly malignancies, who have persistent 
gram-negative bacteremia despite therapy with 
common broad-spectrum antibiotics.
“En Route to Whistler Along the Sea to Sky Highway, British Colombia” 
photograph by Andrew Zabolotsky, MD
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inTroDucTion
AL amyloidosis is a rare disease, with only 1200-3200 
new cases in the US per year.1 Two-thirds of patients 
are male; presentation typically occurs after age fifty.1,2,3 
Amyloid can involve the kidneys (74%), heart (60-90%), 
liver (27%), peripheral nervous system (22%), and carpal 
tunnel (20%).3 We describe an atypical presentation 
of AL amyloidosis and highlight the importance of 
recognizing this disease in patients with systemic signs. 
caSE PrESEnTaTion
A 60 year old Caucasian male was transferred from an 
outside hospital with four months of progressive lower 
extremity burning pain and weakness, unintentional 
34-pound weight loss, fatigue, subjective fevers, night 
sweats and intermittent blood in his stool. Review of 
systems was otherwise negative. Medical, surgical, 
and family history were unremarkable; he took no 
medications. Social history was notable for heavy 
alcohol use until four months prior to admission.
At the outside hospital, the patient had undergone a 
thorough workup for his GI bleeding, which included an 
MRI of his abdomen, esophagogastroduodenoscopy, 
and colonoscopy. Hepatomegaly was noted on the 
abdominal MRI, and several internal hemorrhoids were 
seen on the colonoscopy.
Vital signs were within normal limits. Physical exam was 
notable for cachexia, hepatomegaly, and 3-out-of-5 
strength in the upper and lower extremities. The 
remainder of the exam was normal.
Laboratory evaluation showed a hemoglobin of 8.0 g/
dL (normal range = 14-17 g/dL) with a normal mean 
corpuscular volume, ferritin of 997 ng/mL (normal 
range = 50-150 ng/mL), iron of 29 mcg/dL (normal 
range = 55-160 mcg/dL), and total iron binding capacity 
of 176 mcg/dL (normal range = 250-400 mcg/dL), 
indicating anemia of chronic disease. White blood cell 
count was 9.0 x109/L (normal range = 4-11 x109/L) with 
a normal differential. Platelet count was 1167 x109/L 
(normal range = 140-400 x109/L). Blood smear showed 
Howell-Jolly bodies and thrombocytosis with reactive 
platelets. His electrolytes and creatinine clearance were 
normal. Prothrombin time (PT) was elevated at 36.9 sec 
(normal range = 9.4-12.4 sec), and this did not correct 
with Vitamin K (oral or subcutaneous). His partial 
thromboplastin time (PTT) was high at 51 sec (normal 
range = 28-38 sec). Both PT and PTT corrected with 
mixing studies indicating a factor deficiency. 
Hepatic panel revealed an alkaline phosphatase of 563 
IU/L (normal range = 25-150 IU/L). He was negative 
for HIV, Hepatitis B and C, and syphilis. Serum protein 
electrophoresis (SPEP) showed hypogammaglobu-
linemia with an abundance of lambda light chains; urine 
protein electrophoresis (UPEP) showed a free lambda 
level of 12.26 mg/dL (normal range = 0.02-0.67 mg/
An Uncommon Presentation of Amyloidosis
Brandon Kujawski, MS III, Drew Johnson, MS III, Kushan Radadia, MS IV, Eric Feduska, MD,  
Robert Ford, MD, Guldeep Uppal, MD, Mariam Kabir, MD,PhD, John Stewart, MD
Figure 1. Bone marrow biopsy showing a vessel with deposition 
of pink amorphous material in the wall (Hematoxoylin & Eosin, 
original magnification 400X). There was no evidence of a 
neurogenic process or malignancy. 
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amyloidosis was most likely. Bone marrow biopsy was 
performed, which showed an infiltrate of monoclonal 
lambda positive plasma cells (5%) on immunohisto-
chemical staining, with deposition of amyloid fibers 
in blood vessels (Figure 1). Congo red stain showed 
apple-green birefringence under polarized light 
(Figures 2-3). This led to the diagnosis of light chain 
amyloidosis.
ouTcoME anD Follow-uP
The patient was discharged to a subacute rehabilitation 
facility with plan to follow-up with a hematologist/
oncologist within one week of discharge. No treatment 
plans were made during his hospital stay due to his level 
of deconditioning. Since his gastrointestinal bleeding 
was minimal, intermittent, and he never required 
blood transfusion, his factor deficiency did not require 
correction. 
DiScuSSion
Amyloidosis is caused by the abnormal deposition of 
amyloid protein in a single or multiple organs. Sixty 
different types of amyloid protein have been identified so 
far, and thirty-six have been connected with deposition 
disease.7,8 For example, AA amyloidosis is caused by the 
deposition of an acute phase reactant protein in various 
organs. This acute phase reactant is usually generated 
in the setting of inflammatory disease (inflammatory 
bowel disease, rheumatoid arthritis, etc) or chronic 
infection (tuberculosis, chronic osteomyelitis, etc).9 AL 
dL) indicating a likely plasma cell dyscrasia with lambda 
overproduction. Pro-B-type natriuretic peptide (pro-BNP) 
was 3936 pg/mL (normal range = <100 pg/mL).
CT scans of the thorax, abdomen, and pelvis were 
unremarkable except for an enlarged liver. His bone 
scan and skeletal survey were negative for lytic lesions. 
Electrocardiogram showed normal sinus rhythm with 
intraventricular conduction delay, first-degree AV 
block, and low voltage throughout. A trans-thoracic 
echocardiogram showed an ejection fraction of 60% 
with impaired relaxation of the left ventricle. There was 
no speckled pattern in the myocytes and no restrictive 
cardiomyopathy.
DiFFErEnTial DiagnoSiS
Our differential diagnosis included myelofibrosis, 
essential thrombocytosis, and reactive thrombocytosis 
from a systemic disease such as inflammatory bowel 
disease or amyloidosis. Although multiple myeloma 
was also a concern, the absence of lytic lesions, 
hypercalcemia and renal failure essentially ruled it 
out.4,5 Given the patient’s presentation and laboratory 
abnormalities, Hematology was consulted.
The patient was negative for the JAK2V617F mutation, 
making myelofibrosis or essential thrombocytosis 
unlikely.6 Given the presence of a monoclonal protein 
on SPEP and UPEP, factor X deficiency (5%), and the 
presence of immunoglobulin light chains in the serum 
and urine, a systemic fibril deposition disease such as 
Figure 2 & 3. Bone marrow biopsy showing Congo Red staining (Figure 2) and apple green birefringence in the vessel wall under 
polarized light (Figure 3) (Congo Red stain, original magnification 200X).
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in 60/337 (18%), and gastrointestinal bleeding occurred 
in 16/337 (5%).10
Treatment choices for AL amyloidosis include 
melphalan or cyclophosphamide in conjunction with 
dexamethasone.13 Stem cell transplant (SCT) is offered 
to patients who fit the criteria, which include age <70, 
troponin <0.06, pro-BNP <5000, creatinine clearance 
>30, NYHA Class I or II heart failure, no more than 
two organs involved, no large pleural effusion, and no 
hypoxia.13
The prognosis of patients with AL amyloidosis is poor. 
Without treatment, the median survival is 13 months.13,14 
An Italian study of 705 AL amyloidosis patients who 
underwent treatment showed a median survival of 46 
months. A UK study of 600 patients with treatment 
showed a median survival of 2-3 years.15,16
KEy PoinTS
We present a patient with amyloid deposition disease, 
discuss criteria for the diagnosis of AL amyloidosis, 
and demonstrate how our patient met these criteria. 
In addition, we point out that although AL amyloidosis 
most commonly involves the kidney and the heart, 
there is a less common pattern that affects the liver and 
causes hepatomegaly, coagulopathy and bleeding. It is 
important to recognize this pattern and provide timely 
treatment. In addition, we stress that although there 
are treatment options available for AL amyloidosis, the 
prognosis, even with treatment, is poor.
rEFErEncES
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amyloidosis, on the other hand, is due to deposition 
of protein derived from immunoglobulin light chain 
fragments. It is a plasma cell dyscrasia that can occur 
alone or with multiple myeloma, Waldenstrom’s 
macroglobulinemia, or non-Hodgkin’s lymphoma.2 
The diagnostic criteria for AL amyloidosis include the 
presence of an amyloid-related systemic syndrome, 
positive amyloid staining by Congo red in any tissue, 
evidence that the amyloid is light-chain related, and 
evidence of a monoclonal plasma cell proliferative 
disorder.2 Although the most definitive proof of light 
chain amyloid is by mass spectrometry of a biopsy 
sample, immunohistochemical staining of the sample 
can also be used for diagnosis.10 Our patient met all 
of the above criteria, as follows. He had evidence 
of liver involvement, cardiac involvement (low 
voltages, first degree AV block), and likely peripheral 
neuropathy. There was evidence of amyloid by Congo 
red staining. Immunohistochemical staining of his 
bone marrow showed plasma cells with lambda light 
chain predominance. In addition, he had excessive 
lambda light chains in his serum and urine, indicating 
monoclonal plasma cell proliferation. We did not send 
a sample for mass spectrometry. 
AL amyloidosis with liver involvement has several 
interesting features. A review of patients with AL 
amyloidosis analyzed a total of 98 patients with 
hepatic involvement.11 Among these, 71% had weight 
loss and hepatomegaly; our patient had both of these. 
Laboratory studies showed alkaline phosphatase 
elevations in 86% of patients; AST/ALT were only 
elevated in 37% of patients. Our patient only had an 
alkaline phosphatase elevation. Amyloidosis also led to 
functional hyposplenism with reactive thrombocytosis 
in ~28% of patients. A classic hematologic finding in 
these patients on peripheral blood smear was the 
presence of Howell-Jolly bodies, as were seen on our 
patient’s blood smear.
A unique finding in our patient was the prolonged PT 
with associated gastrointestinal bleeding, which was 
found to be secondary to factor X deficiency. A study 
looking at acquired factor X deficiency in patients with 
AL amyloidosis, found that 32/368 (8.7%) had factor X 
deficiencies.12 Another study of 337 patients done by 
Mumford et al10 found that 172/337 had prolonged PT, 
PTT, or thrombin time. Cutaneous bleeding occurred 
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inTroDucTion
Transjugular intrahepatic portosystemic shunt (TIPS) is 
a common procedure used to alleviate the secondary 
effects of portal hypertension including uncontrolled 
variceal bleeding, refractory ascites, and hepatic pleural 
effusion (hydrothorax). There are several well-known 
complications of TIPS, including portosystemic enceph-
alopathy, hemolytic anemia, hepatic ischemia, and stent 
thrombosis.1 In this case report we present a rare but 
serious complication of TIPS – bilhemia - in which bile 
escapes into the bloodstream through a fistula between 
the biliary tree and the hepatic venous system.
caSE PrESEnTaTion
A 56 year-old female with cirrhosis due to chronic 
hepatitis C presented to the hospital for a scheduled 
esophagogastroduodenoscopy (EGD) for evaluation and 
banding of esophageal varices. During the procedure, a 
large varix ruptured, requiring the patient to undergo an 
emergent TIPS procedure to control the hemorrhage. 
A TIPS was attempted using a 10mm x 10mm Viatorr 
covered stent. In the operative report, the interventional 
radiologist noted that multiple unsuccessful attempts were 
made accessing the right portal vein, requiring repeated 
repositioning of the cannula. Ultimately, a successful 
bridge was created between the right hepatic vein and 
central portal vein, which reduced the portosystemic 
gradient from 14 mmHg to 3 mmHg. The patient was 
stabilized hemodynamically with a transfusion of seven 
units of packed red blood cells and was admitted to the 
medical intensive care unit (MICU). 
Three days following the procedure the patient became 
jaundiced. Her laboratory profile at that time showed that 
her total and direct bilirubin levels had increased almost 
10-fold, while her transaminases and INR remained stable 
(Table 1). An abdominal ultrasound was performed to 
evaluate the stent, which was found to be patent. There 
was also no evidence of biliary obstruction/dilatation 
on ultrasound. Over the course of her hospital stay, the 
patient’s bilirubin continued to rise (Figure 1) while her 
alkaline phosphatase, transaminases, and INR remained 
stable (Figures 2-3). The continual rise in bilirubin 
prompted an abdominal CT, which showed a patent 
TIPS and no evidence of hepatic ischemia or biliary duct 
dilatation.
DiFFErEnTial DiagnoSiS
Elevated direct bilirubin levels are typically a sign 
of hepatocellular or biliary injury/obstruction. After 
undergoing TIPS placement, the shunting of blood 
from the portal vein to the systemic circulation can 
occasionally lead to hepatic ischemia.1 Clinically, this 
A Case of Bilhemia: A Rare Complication of 
Transjugular Intraheptic Portosytemic Shunt
Michael Zhang, MS III, Michael A. Valentino, MD, PhD
Table 1. Liver function tests pre-TIPS and three days post-TIPS. 
Antibiotic Pre-TIPS (normal range) 3 Days Post-TIPS
Total bilirubin (mg/dL) 1.4 (0.1-0.9) 12.2
Direct bilirubin (mg/dL) 0.6 (0.0-0.3) 9.1
Alkaline phosphatase (U/L) 58 (25-120) 90
AST (U/L) 144 (7-42) 139
ALT (U/L) 37 (1-45) 57
INR 1.66 (0.79-1.21) 1.15
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presents as worsening right upper quadrant abdominal 
pain, hepatic encephalopathy, elevated aspartate 
transaminase (AST) and alanine transaminase (ALT) 
levels as well as an elevated serum bilirubin.1-2 However, 
the patient had an isolated hyperbilirubinemia, without 
transaminase elevation or worsening synthetic liver 
function. In addition, she had no abdominal pain and 
demonstrated no signs of encephalopathy. Therefore it 
was determined that hepatic ischemia was an unlikely 
diagnosis. To that same effect, worsening cirrhosis was 
equally unlikely as the patient demonstrated neither 
deterioration in her synthetic liver function nor any 
clinical signs of decompensated cirrhosis such as ascites 
or encephalopathy. Moreover, worsening cirrhosis 
post-TIPS is typically associated with TIPS thrombosis or 
stenosis, and both the ultrasound and CT scan showed 
a patent TIPS.3
Biliary tree stricture or blockage is another condition that 
can lead to hyperbilirubinemia. Again, we considered this 
unlikely due to the patient’s isolated hyperbilirubinemia, 
normal alkaline phosphatase level, as well as a lack of 
bile duct dilatation on ultrasound and CT scan. 
Bilhemia is a rare condition which presents with sudden 
jaundice and a rapid elevation in direct bilirubin without 
evidence of hepatocellular injury or biliary obstruction.3 
It was determined that this was the likely diagnosis given 
the patient’s rapidly rising bilirubin levels in the setting 
of otherwise unchanged liver function tests and no 
evidence of obstruction on imaging. Furthermore, the 
biliary-venous fistula could be explained by the difficulty 
encountered in cannulating the portal vein during the 
TIPS procedure.
ouTcoME anD Follow-uP
Fifteen days after the TIPS procedure, an ERCP was 
performed to evaluate for evidence of a biliary-venous 
fistula. The cholangiogram did not show evidence of a 
fistula or bile duct dilatation. However, a common bile duct 
stent was placed and sphincterotomy was performed in 
an attempt to lower the biliary pressure in order to reduce 
the flow of bile through a potentially unseen fistula. 
Despite this procedure, the patient’s bilirubin continued 
to rise, and a venogram was performed to visualize and 
occlude the biliary-venous fistula. The venogram was 
also unremarkable, and it was determined that the only 
Figure 1. Total and direct serum bilirubin levels post-TIPS
Figure 2: Serum alkaline phosphatase and hepatic transaminases 
post-TIPS
Figure 3: INR post-TIPS
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other cases reports of TIPS-induced bilhemia. In this case, 
biliary stenting and sphincterotomy was unsuccessful 
in managing the condition. Liver transplantation was 
determined to be the only option for treatment; however 
the patient’s persistent bacteremia eliminated the 
possibility of transplant. 
KEy PoinTS 
Bilhemia is a rare complication of TIPS which should be 
suspected in post-TIPS patients with a rapid rise in serum 
bilirubin without other signs of hepatic dysfunction. The 
formation of a biliary-venous fistula can lead to thrombo-
embolism and bacteremia. Decompression of the biliary 
tree should be attempted, and liver transplantation should 
be prioritized as this condition is fatal in ~50% of cases.6
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viable way to reverse the bilhemia was through liver 
transplantation.
During her hospital course, the patient developed a 
resistant Klebsiella bacteremia. Even with appropriate 
treatment, she remained persistently bacteremic, likely 
due to seeding of her TIPS. She developed sepsis 
complicated by renal failure and was transferred back 
to the MICU. Unfortunately, the patient’s infection 
precluded her from undergoing liver transplantation and, 
after multiple discussions with the patient and her family, 
she was ultimately discharged home with hospice care.
DiScuSSion
Bilhemia is a condition characterized by a rapid rise in 
total and direct serum bilirubin without other signs of 
hepatic dysfunction or biliary obstruction.4 It is typically 
a consequence of hepatic trauma, though it has been 
known to occur as a complication of TIPS procedures.5 
The pathophysiology relates to a pressure gradient 
between the common bile duct (mean pressure = 12-14 
mmHg) and the hepatic vein (mean pressure = 7 mmHg) 
which results in the direct flow of bile into the hepatic 
vein.4, 6 This is in contrast to a fistulous communication 
between the higher pressure portal venous system and 
the biliary tree which typically results in hemobilia (flow of 
blood into the biliary system). 
One consequence of bilhemia is fat embolism from the 
passage of large amounts of undissolved bile into the 
systemic circulation.6-7 Bacteremia is another consequence 
and is thought to be caused by the bilious contamination 
of the systemic circulation with enteric flora.8-10 
Treatments for bilhemia aim to decompress the biliary 
system, commonly with biliary stenting and sphinc-
terotomy.6-8 Other case studies have shown that 
percutaneous biliary drainage, endoscopic nasobiliary 
drainage, and venous balloon occlusion are also viable 
options with liver transplantation being the only definitive 
treatment for bilhemia.4-5,7-8 In the absence of treatment, 
spontaneous closure of the biliary-venous fistula within 
three weeks has been observed.7 
The patient’s sudden jaundice and rapid rise in bilirubin 
three days after TIPS matches the clinical presentation of 
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Congenital Absence of the Pericardium
Lillian C. Man, MD, Jaehee Kim MD, Rakesh Gupta, MD
inTroDucTion
Congenital absence of the pericardium (CAP) 
is an uncommon finding previously recognized 
only post-mortem or during surgery. However, its 
incidence has been on the rise with the use of multiple 
contemporary imaging techniques. CAP can present 
with paroxysmal, left-sided chest pain and should be 
considered in the differential diagnosis of atypical causes 
of chest pain. We present the case of a 50-year-old 
male who presented with chest pressure, symptoms of 
heart failure, and was found to be in atrial fibrillation 
in whom partial absence of the left pericardium was 
diagnosed. 
caSE PrESEnTaTion
A 50 year-old African-American male presented to 
the Emergency Department with a chief complaint 
of shortness of breath (SOB) and worsening dyspnea 
on exertion for one week. He described worsening 
SOB when lying on his left side, as well as palpitations, 
orthopnea, and non-radiating, left-sided chest pressure. 
On physical exam, the patient was tachycardic with an 
irregularly irregular heart rate, crackles in the lower 
lobes, trace bilateral lower extremity edema, and a 
non-palpable apical impulse. Laboratory studies were 
significant for a pro-B-type natriuretic peptide (pro-BNP) 
level of 2830 pg/mL (normal range = <100 pg/mL) and 
negative troponins. Electrocardiogram (ECG) showed 
a ventricular rate of 146 beats per minute, irregularly 
irregular rhythm, right axis deviation, and poor R-wave 
progression. Chest x-ray (CXR) (Figure 1) revealed 
cardiomegaly and a diminished right heart border. 
Subsequent echocardiogram showed severe mitral 
regurgitation and moderate tricuspid regurgitation. Of 
note, it also showed the heart shifted posteriorly in the 
apical window, suspicious for congenital absence of 
pericardium. CT scan confirmed the diagnosis of partial 
absence of the left pericardium.
DiScuSSion
Congenital absence of the pericardium is a rare entity 
formerly recognized only at autopsy or during surgery1, 
with about 400 reported cases in the literature. Up to 
70-80% of pericardial defects involve the left side and are 
due to premature atrophy of the left common cardinal 
vein during embryologic development.2 About one-third 
of all cases of CAP are described in association with 
other cardiac defects, such as patent ductus arteriosus, 
mitral stenosis, and tetralogy of Fallot.3,4 
The clinical presentation of symptomatic patients tends 
to be non-specific. Patients with partial CAP may have 
dyspnea and trepopnea, or the presence of dyspnea 
when the lying on one side, which our patient had.4 
A number of case reports also described patients who 
presented with left-sided chest pain of varying quality, 
Figure 1: Admission chest X-ray
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such as stabbing, throbbing, postural, or exertional.3,5 In 
other case reports, patients have reported the sensation 
of a "shifting heart". Since the pericardium provides 
structural support for the heart, its complete or partial 
absence allows the cardiac apex to move posteriorly 
or laterally, leading to a significantly displaced or 
non-palpable apical impulse,3,4,6 which our patient had.
Interestingly, patients with complete absence of the 
pericardium tend to be asymptomatic. 
ECG findings may show right-axis deviation, right 
bundle branch block, and poor R-wave progression.2 
These findings are related to the posterior displacement 
of the left ventricle, allowing the right heart to become 
more prominent anteriorly. CXR can show levoposition 
in which the heart is shifted laterally and into the left 
chest, leading to an absent right heart border. The left 
cardiac border may be straightened and elongated, 
known as the “Snoopy sign.” Echocardiogram may 
show what appears to be a dilated right ventricle due to 
its anterior location and abnormal interventricular septal 
motion.5,7,8 CT or cardiac MRI are the best diagnostic 
tools for pericardial absence, with cardiac MRI being 
the gold standard.7
Management depends on the size of the pericardial 
defect and presence or absence of symptoms. 
Patients with a partial pericardial absence are at risk 
for entrapment of the heart through the defect. This 
can lead to strangulation of the atria, appendages, 
and ventricles, causing sudden death in the most 
severe cases.7,9,10. Patients without such significant 
complications can still experience bothersome, sharp, 
left-sided chest pain. Surgical pericardioplasty is usually 
reserved for symptomatic patients or those with partial 
defects in which herniation is an imminent risk.2 On the 
other hand, patients with a large or complete pericardial 
defect can usually be safely observed because of a 
lower risk of herniation and incarceration of cardiac 
structures. 
KEy PoinTS
Although CAP is usually an incidental finding, 
awareness of it is important for a number of reasons. 
Patients with partial defects may experience disabling, 
left-sided chest pain without obvious cause. In the 
most severe cases, the atria, appendages, or ventricles 
may herniate through the pericardial defect, leading 
to sudden death. Given that CAP has a nonspecific 
clinical presentation but the potential for severe 
complications, maintaining a high index of suspicion is 
important in diagnosing and managing this condition 
in symptomatic patients. 
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Recurrent Cryptococcosis in a Human 
Immunodeficiency Virus-negative Patient
Lillian C. Man, MD
Acknowledgements: Dr. Jeffrey B. Baliff, Jefferson University Department of Pathology
inTroDucTion
Idiopathic CD4+ lymphocytopenia (ICL) is a rare 
disorder that can predispose otherwise immunocom-
petent individuals to life-threatening opportunistic 
infections. We present a case of a human immuno-
deficiency virus (HIV)-negative patient with ICL who 
presented with recurrent cryptococcosis. 
caSE PrESEnTaTion
A 39-year-old Caucasian, HIV-negative male with a past 
medical history of stroke 13 years prior to admission and 
an episode of cryptococcal meningitis 18 months prior 
to admission presented to the hospital with generalized 
weakness for 7 days. The patient had a 10 pack-year 
smoking history and no significant environmental or 
occupational exposures. On admission, vital signs were 
significant for a temperature of 101.1oF, a heart rate of 
117 beats per minute, and a blood pressure 93/75 mm 
Hg. Physical exam was remarkable for an ill-appearing 
male with dry mucous membranes and tachycardia.
Initial laboratory studies were significant for a white blood 
count of 3.14 cells/µL (normal range = 4.5-11 cells/µL), 
hemoglobin of 8.7 g/dL (normal range = 13.5-17.5 g/
dL), and creatinine of 5.2 mg/dL (normal range = 0.6-1.2 
mg/dL). Blood cultures were positive for Cryptococcus 
neoformans. Subsequent laboratory studies revealed a 
serum cryptococcal antigen titer of 1:256 and a CD4+ 
count of 227 cells/µL (normal range = 410-1590 cells/
µL). The CD4+ count was 98 cells/µL when the patient 
was diagnosed with cryptococcal meningitis 18 months 
prior. Enzyme-linked immunosorbent assays for HIV 
were negative. Anti-nuclear antibody titer was 1:80 and 
anti-double stranded DNA, anti-Smith, anti-SSA, anti-SSB 
, and anti-ribonucleoprotein antibodies were negative. 
Lumbar puncture (LP) showed a normal opening pressure 
and was negative for cryptococcal infection.
Chest X-ray revealed a right pleural mass. Subsequent 
CT of the thorax revealed a 6.3 x 3.3 cm pleural-based 
mass in the right upper lobe of the lung (Figure 1). Due 
to suspicion for a pulmonary malignancy, a Technetium 
bone scan was performed and found increased uptake 
in the right femur and left humerus. X-ray of the right 
femur showed well-circumscribed lytic lesions in the 
mid-femoral diaphysis (Figure 2). CT-guided biopsy 
of the pleural mass and the femur lesion revealed 
narrow-based, budding yeast that stained Gomori 
methenamine silver (Figure 3a) and a capsule that 
stained red with mucicarmine (Figure 3b), consistent 
with a diagnosis of cryptococcosis. 
ouTcoME anD Follow-uP
The patient was treated with a four-week course of 
liposomal amphotericin B and flucytosine and then 
discharged on fluconazole. He was also recommended 
to follow up at the National Institutes of Health (NIH) 
for further work-up of ICL as the predisposing etiology 
of his recurrent cryptococcosis.
Two months af ter discharge, the patient was 
hospitalized at an outside hospital for muscle pain and 
Figure 1: CT thorax without contrast showing a right pleural 
mass (arrow).
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was still undergoing evaluation. He had not followed 
up at the NIH yet and was still on fluconazole therapy.
DiScuSSion 
ICL is a rare disorder first defined by the US Centers 
for Disease and Control in 1992 as a CD4+ count 
<300 cells/mm3 or a CD4+ cell count < 20% of total 
T-cells on two occasions and no serologic evidence 
of HIV infection.1 The pathogenesis of ICL remains 
unclear. Researchers suggest a multifactorial etiology 
from diminished T-cell precursors, increased CD4+ 
lymphocyte apoptosis, and genetic factors.2,3 There 
is also an association between autoimmune diseases 
and ICL, most commonly Sjogren’s. However the 
mechanism by which autoimmunity contributes to 
ICL’s pathogenesis is ill-defined.2 Some reports suggest 
IL-2 therapy may increase CD4+ counts as well as 
decrease susceptibility to opportunistic infections, but 
currently there are no clear strategies to increase CD4+ 
lymphocytes.3
The most important differential diagnosis for ICL is HIV 
infection. ICL typically becomes apparent through the 
manifestation of opportunistic infections, the most 
prevalent of which are cryptococcosis, mycobacte-
riosis, and herpes zoster.4 Disseminated cryptococcosis 
can affect multiple organ systems including the adrenal 
glands, prostate, and bones and may be mistaken for 
malignancy with metastasis, 5 as was the case with our 
patient. Given that meningitis is the most common 
presenting illness in patients with cryptococcosis, 
LP is essential even in the absence of neurological 
symptoms.6,7 Untreated cryptococcal meningitis carries 
a high mortality rate and can lead to cranial nerve 
palsies, hearing loss, and blindness.8 
According to the current Infectious Diseases Society of 
America guidelines, non-HIV patients with disseminated 
cryptococcosis should be treated with a four-week 
course of amphotericin B and flucytosine for induction 
therapy followed by maintenance therapy with 
fluconazole for 6-12 months.7 However, the recommen-
Figure 3a: Gomori methenamine silver (GMS) of the pleural 
mass biopsy showing innumerable darkly stained yeast. 
Figure 3b: Mucicarmine stain of the pleural mass biopsy. Multiple 
budding yeast are shown (circled).
Figure 2: X-ray of right 
femur. Lytic lesions are 
shown (circled).
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dations for non-HIV patients with cryptococcosis are 
often based on studies of HIV-infected patients. Given 
that our patient presented with recurrent crypto-
coccosis in the presence of ICL, it was thought that he 
should be maintained on fluconazole indefinitely.
KEy PoinTS
In summary, ICL patients can present with an array of 
opportunistic infections even in the absence of HIV. The 
pathogenesis of ICL remains unclear, and guidelines 
on the treatment of ICL patients with opportunistic 
infections are largely based on studies of HIV-infected 
patients. Cryptococcosis is one of the most common 
opportunistic pathogens that infect ICL patients. 
Patients with cryptococcosis should have an LP even 
in the absence of neurologic symptoms due to the 
high morbidity and mortality of untreated cryptococcal 
meningitis.
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A Case of Dengue Hemorrhagic Fever  
and the Use of Supportive Therapy 
Aishah Ali, MD, Emily Sutton, MD
inTroDucTion
Dengue fever is a mosquito-bound viral illness that 
occurs in tropical climates. It is endemic in 110 
countries.1 Fifty to three hundred and ninety million 
people are infected worldwide every year,2 leading to 
~25,000 deaths.3 It is often an asymptomatic self-limited 
illness, which can present with myalgias, arthralgias, 
and hemorrhagic manifestations such as petechiae. In a 
fraction of cases, dengue fever can proceed to dengue 
hemorrhagic fever (DHF), which can be life threatening 
causing thrombocytopenia, bleeding and increased 
vascular permeability. Dengue shock syndrome (DSS) 
can then ensue, if hypotension occurs, and is fatal in 
>10% of patients.4
Here we present a case of Dengue fever, which 
proceeded to DHF and finally DSS. Our case 
demonstrates the supportive nature of treatment and 
how catastrophic severe dengue fever can be.
caSE PrESEnTaTion
A 64 year-old Pakistani female with a history of diabetes 
mellitus presented to her local hospital with severe 
body aches and malaise three days after returning 
from a two month long trip to Pakistan. During her 
stay, several family members had a self-limited febrile 
illness and one was diagnosed with dengue fever. On 
admission she was found to be febrile and thrombocy-
topenic, raising concern for dengue fever. She rapidly 
deteriorated with acute renal failure, acute liver failure 
(Table 1), new onset seizures, and required intubation 
and mechanical ventilation. She was then transferred 
to Thomas Jefferson University Hospital where she was 
emergently started on molecular adsorbent recycling 
system (MARS) therapy and continuous veno-venous 
hemodialysis (CVVHD).
Table 1. Labs on Admisssion
Lab Parameter Value (normal range) Lab Parameter Value (normal range)
AST 11035 IU/L (7 – 35) Sodium 138 mmol/L (135-146)
ALT 1925 IU/L (1 – 30) Potassium 3.3 mmol/L (3.5 – 5)
Total Bilirubin 6.5 à 14.7 mg/dL (0.1 – 0.9) Chloride 84 mmol/L (89 – 109)
Direct Bilirubin 5.3 à 13.2 mg/dL (0.0 – 0.3) Bicarbonate 13 mmol/L (24 – 32)
Alkaline phosphatase 230 à 239 IU/L (25 – 120) BUN 22 mg/dL (7 – 26)
GGT 254 IU/L (5 – 55) Creatinine 2.3 mg/dL (0.7 – 1.4)
LDH 8490 IU/L (105 – 333) Glucose 179 mg/dL (70 – 100)
Lactate 27.6 mmol/L (0.5 – 2.2) Anion Gap 13 mmol/L (4 – 16)
PT 25.9 seconds (8.6 – 13.0) WBC 6.7 B/L (4 – 11)
INR 2.44 sec (0.79 – 1.21) Bands 30 % (0 – 9)
PTT 39 sec (28 - 38) Hemoglobin 8.4 g/dL (12.5 – 15)
Fibrinogen 180 mg/dL (203 - 451) Hematocrit 25.5 % (36 – 46)
D dimer 2661 ng/mL (<331) Platelets 33 B/L (140 – 400)
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week with the hope that longer therapy would improve 
her outcome. Her hospital course was complicated by 
tracheobronchitis and septic shock requiring multiple 
vasopressors.   As she still had no sign of neurologic 
recovery, the family decided to withdraw life support. 
DiFFErEnTial DiagnoSiS
The patient’s recent history of travel suggested an 
infectious etiology, particularly dengue as it is endemic 
in Pakistan. In addition, history obtained provided 
evidence of a local outbreak. Furthermore, her timeline 
of fevers and thrombocytopenia 3-7 days after her 
return supported the diagnosis of DHF. The incubation 
period for dengue is typically 3-14 days.5 Congo fever 
was also considered but was less likely as it isn’t 
commonly seen in the area she visited in Pakistan. As 
her hospital course progressed and she became more 
thrombocytopenic with increasing evidence of severe 
vascular permeability (Figure 1), the diagnosis of DHF 
became more apparent. In addition, her serum dengue 
IgG and IgM were reported positive several days after 
admission.
ouTcoME anD Follow-uP 
Although her aminotransferase levels improved rapidly 
on MARS (Table 2), the patient’s hospital course was 
complicated by seizures and a new large ischemic 
stroke in the left medial temporal region. After one week 
of MARS therapy with no improvement in her mental 
status, she underwent a transjugular liver biopsy that 
showed 50-75% necrosis of liver parenchyma. Given her 
poor prognosis secondary to severe dengue infection, 
as well as the aforementioned stroke, she was deemed 
unsuitable for liver transplant. Post-ischemic stroke she 
did not have focal deficits, but it was difficult to fully 
neurologically assess her because of unresponsiveness. 
She was maintained on MARS/CVVHD for one more 
Figure 1. The tourniquet test also known as the capillary-fragility 
test. Seen in areas of pressure, such as tourniquets or blood 
pressure cuffs.
Table 2: Lab Values Pre and Post Therapy
Lab Pre-supportive Therapy (normal range) Post-supportive therapy (normal range)
AST 10705 IU/L (7 – 35) 101 IU/L (7 – 35)
ALT 1924 IU/L (1 – 30) 73 IU/L (1 – 30)
Total Bilirubin 6.5 mg/dL (0.1 – 0.9) 14.7 mg/dL (0.1 – 0.9)
Direct Bilirubin 5.3 mg/dL (0.0 – 0.3) 13.2 mg/dL (0.0 – 0.3)
Lactate 24.8 mmol/L (0.5 – 2.2) 7.2 mmol/L (0.5 – 2.2)
Creatinine 2.3 mg/dL (0.7 – 1.4) 0.8 mg/dL (0.7 – 1.4)
Pre-support therapy: before MARS and CVVHD were initiated 
Post-supportive therapy: after MARS and CVVHD were initiated
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type of waste product from the circulation. SPAD uses 
a standard renal replacement machine with an albumin 
dialysate solution and no additional recirculation pump, 
whereas MARS uses standard dialysis solution, an 
albumin solution, and an additional recirculation pump. 
MARS and SPAD were both efficient in vitro at removing 
albumin-bound substances, such as bilirubin; SPAD was 
actually superior to MARS in removing bile acid waste. 
Both SPAD and CVVHDF were better than MARS in taking 
out water-soluble solutes such as ammonia. The most 
notable difference was that SPAD cost significantly less 
than MARS; for a seven-hour session, SPAD cost $810 
whereas MARS cost $2641. In our patient, MARS was 
an expensive treatment to continue without any proven 
correlation between prolonged length of use and 
improvement in mortality. Cost-effectiveness must be 
taken into consideration when alternate therapies are 
available for fractions of the cost.
As an adjuvant therapy for her fulminant hepatic failure, our 
patient also received eight days of N-acetylcysteine (NAC). 
NAC has been shown to be beneficial in patients when 
liver transplant is not available for non-acetaminophen 
associated acute liver failure. In a retrospective analysis 
of eight patients with dengue-associated acute liver 
failure, NAC was shown to be beneficial in early stages 
of liver failure but not in advanced stages.10 The patient 
in this analysis had a maximum length of NAC use of 72 
hours. No analysis exists comparing MARS versus NAC, 
or using both treatments, for improved outcomes in 
acute liver failure. 
KEy PoinTS
The treatment for dengue hemorrhagic fever is entirely 
supportive. Guidelines for the length of MARS treatment 
in dengue patients in fulminant hepatic failure needs to 
be further evaluated, as MARS is an expensive treatment 
only available at a few tertiary level centers. 
DiScuSSion
Dengue fever is caused by the dengue virus, which is 
carried by several species of the mosquito in the genus 
Aedes. Classic dengue fever is a self-limited febrile 
illness that may last up to one week. However, it can 
become more severe and proceed to the hemorrhagic 
form where profound increases in vascular permeability 
can lead to shock and possibly multi-organ failure. 
The mechanism behind the vascular permeability 
is unknown but is thought to be secondary to the 
overwhelming inflammatory response to the virus.6
The treatment for dengue is entirely supportive, 
consisting of aggressive fluid resuscitation. MARS and 
CVVHD therapy may also be used for life threatening 
sequelae with potential improvement of acute 
liver failure, acute kidney failure, and disseminated 
intravascular coagulation.5
There is little evidence regarding the use of MARS in the 
setting of dengue fever. One case report demonstrated 
rapid improvement in a patient with dengue-associated 
hepatic encephalopathy and fulminant hepatic failure 
after treatment with MARS and CVVHD.7 The patient’s 
transaminitis rapidly corrected with MARS, with 
associated resolution of hepatic encepathopathy. The 
length of MARS with concurrent CVVHD in this case 
was three days. In our patient, MARS therapy corrected 
the transaminitis but did not affect her mental status. 
It was also surprising that her bilirubin levels remained 
elevated despite MARS which usually removes 
albumin-based substances such as bilirubin and bile 
acids.8 It was unclear if her altered mental status was 
secondary to hepatic encephalopathy, stroke, uremia, 
or infection. 
In hindsight, MARS may not have been indicated in 
this patient for an additional week after no clinical 
improvement in the first few days. There are no clear 
guidelines on the use of MARS or hemodialysis in a 
patient with acute liver failure. In one study evaluating 
the improvement in mental status in patients with acute 
liver failure and encephalopathy who were placed on 
hemodialysis, 61.5% had either total (43.6%) or partial 
(17.9%) regaining of consciousness.9 Comparisons 
have been made between MARS in combination with 
continuous veno-venous hemodiafiltration (CVVHDF), 
CVVHDF alone, and single-pass albumin dialysis (SPAD).7 
All three forms are similar because they remove some 
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A Speedy Recovery with Medical Management  
in a Patient with Emphysematous Gastritis
Tanvi Khurana, MD
inTroDucTion
Emphysematous gastritis is a rare and serious condition 
characterized by evidence of intramural air and 
inflammation of the gastric wall as well as systemic 
toxicity. It is generally caused by local infection by 
gas-forming organisms through a mucosal defect or 
via hematogenous spread from a distant focus.1 Since 
emphysematous gastritis has a fulminant course with 
a mortality rate of 60%, prompt recognition as well as 
early treatment are crucial.2 Here, we present a case of 
a 65 year-old male who presented with abdominal pain 
and had CT findings consistent with emphysematous 
gastritis. He was treated with antibiotics and had a swift 
recovery.
caSE PrESEnTaTion
A 65-year-old Caucasian man with past medical history 
of insulin-dependent diabetes, hypertension, hyperlip-
idemia, coronary artery disease (with history of three 
myocardial infarctions and stent placements), and peptic 
ulcer disease presented to Thomas Jefferson University 
Hospital with two weeks of loose stools and two days 
of nausea, vomiting and diffuse abdominal pain. In the 
emergency room, the patient had a temperature of 
96.8oF, heart rate of 99 beats per minute, blood pressure 
of 95/58 mmHg, respiratory rate of 22 breaths per 
minute, and oxygen saturation of 96% on 3L of oxygen. 
His cardiac and respiratory exams were unremarkable. 
His abdominal exam was notable for hypoactive bowel 
sounds and pain with deep palpation. He was tympanic 
to percussion. He did not have peritoneal signs. Labs 
were significant for a white blood cell count of 11.3 B/L 
(normal range = 4-11 B/L) and lactate of 1.0 mmol/L 
(normal range = 0.5-2.2 mmol/L) on presentation, 
which was repeated 6 hours later and found to have 
increased to 2.5 mmol/L. He underwent a CT scan of 
the abdomen which revealed a distended stomach with 
foci of intramural air, with air extending into the portal 
venous system (Figure 1). Soon after presentation, 
Figure 1. CT scan of the abdomen demonstrating air in the 
portal venous system as well as in the gastric wall.
Figure 2. CT scan of the abdomen demonstrating resolution of 
all air on day 2 of hospitalization
26
The Medicine Forum, Vol. 15 [2015], Art. 29
http://jdc.jefferson.edu/tmf/vol15/iss1/29
 The Medicine Forum  |   25 5
the patient became hypotensive to a systolic blood 
pressure of 85 mmHg and was resuscitated with 3L 
normal saline. He was sent to the intensive care unit 
where he received an additional 2L normal saline. 
His blood pressure responded appropriately. Surgery 
was consulted regarding the intramural air found on 
CT scan. However, since the patient did not have 
an acute abdomen, they deemed that he would not 
need emergent surgery. It was also decided that an 
esophagogastroduodenoscopy (EGD) would be too 
high risk given the increased risk of perforation. He 
was medically managed with antibiotics and supportive 
care. He was allowed nothing-by-mouth, pan- cultured, 
and started on a pantoprazole infusion and broad 
spectrum antibiotics (vancomycin, aztreonam, and 
metronidazole.
DiFFErEnTial DiagnoSiS
The significance of radiographic findings showing 
intramural air within the gastric wall is based entirely 
on the clinical situation. Intramural air in a patient who 
recently underwent instrumentation of their gastro-
intestinal tract significantly differs from intramural 
air found in an ill, septic patient. The differential 
for intramural air within the gastric wall includes 
emphysematous gastritis, as in our case report, versus 
cystic pneumatosis versus gastric emphysema.
ouTcoME anD Follow uP
By day 2 of hospitalization, our patient had clinically 
improved with less abdominal pain and no further 
vomiting. Blood cultures were negative. A repeat CT 
scan showed resolution of gas in the stomach wall and 
portal venous system but showed new wall thickening of 
the proximal ascending colon (Figure 2). It was thought 
that the patient had bowel ischemia as a result of the 
emphysematous gastritis. By day 3 of hospitalization, our 
patient was restarted on a diet, which he tolerated well. He 
finished a 10-day course of antibiotics and had complete 
resolution of all his symptoms. He was discharged home 
with outpatient gastroenterology follow-up.
DiScuSSion
Emphysematous gastritis is described as gas in the lining 
of the stomach wall by gas-producing organisms caused 
by local spread of the organisms through the mucosa 
or by hematogenous dissemination from a distant 
focus.3,5 Emphysematous gastritis was first described in 
1889 by Frankel who believed it was caused from an 
infection where a prior insult to the mucosal barrier had 
occurred, either by corrosives, alcohol abuse, gastric 
ulcers, abdominal surgery, malignancy or gastroen-
teritis.4,5 Gas within the GI tract occurs most often in 
the descending and sigmoid colons, while the stomach 
is the least common hollow organ for intramural air to 
occur due to the acidic environment.
Common organisms involved in emphysematous 
gastritis include Enterobacter species, Pseudomonas 
aeruginosa, Candida albicans, Staphylococcus aureus, 
Streptococci, and Escherichia coli. Patients usually 
present with gastrointestinal signs and symptoms with 
abdominal pain, distension, bloating, diarrhea, nausea 
and vomiting.2,3,6 Diagnosis is usually based on the 
clinical history, a physical exam suggestive of an acute 
abdomen and imaging showing gas in the gastric wall 
and portal venous system, with CT scan being the most 
sensitive imaging modality.3 Characteristic findings 
include cystic pockets or streaks of air within the gastric 
wall with thickened mucosal folds, pneumoperitoneum, 
portal venous gas and occasionally pneumatosis 
intestinalis.2,6 
Unlike gastric emphysema, which is defined as gas in 
the stomach lining with no associated infection and 
has an excellent prognosis with medical management, 
emphysematous gastritis is rare and has a high mortality 
rate. Surgery should be avoided during the acute phase 
in the absence of bowel perforation due to the friability 
of the mucosa. It is important to treat patients based 
on their clinical condition and to initiate antibiotics 
early as mortality rates are as high as 75%.1 Thus, early 
recognition of the illness, application of broad-spectrum 
antibiotics and meticulous supportive care are regarded 
as key therapeutic measures.7
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KEy PoinTS
Emphysematous gastritis is described as gas in the 
lining of the stomach wall caused by gas-producing 
organisms. It can be caused by an infection where a 
prior insult to the mucosal barrier has occurred, either 
by corrosives, alcohol abuse, gastric ulcers, abdominal 
surgery, malignancy or gastroenteritis. Diagnosis is 
usually made based on the clinical picture, a physical 
exam suggestive of an acute abdomen, and imaging 
showing gas in the gastric wall and portal venous 
system.
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A Case of Fibrosing Mediastinitis
Esther Molnar, MD
inTroDucTion
Fibrosing mediastinitis (FM) is a rare disease of slowly 
progressive fibrosis that encases major mediastinal 
structures. Complications include obstruction of 
mediastinal vasculature, including main pulmonary 
arter ies,  which may lead to l i fe-threatening 
hemodynamic compromise. In North America, the 
disease is usually a sequela of histoplasmosis. Because 
Histoplasma capsulatum (H. capsulatum) is found in the 
Ohio River Valley, physicians in Pennsylvania must be 
able to recognize and diagnose the disease.
caSE PrESEnTaTion
The patient is a 59 year-old female who was seen for 
follow-up in April 2013. She originally presented to the 
outpatient office in 2008 with chronic chest pain and 
shortness of breath. At that time her chest pain was 
constant, stabbing, non-pleuritic, located over the right 
anterior chest wall with radiation to the back, and was 
relieved with narcotic pain medications. She also had 
dyspnea on exertion. She described these symptoms 
as having been present for two years and noted that 
they had been getting progressively worse. On review 
of symptoms, she also noted light headedness with 
standing, occasional palpitations, and a dry cough. She 
denied weight loss, fevers, chills, hemoptysis, or lower 
extremity edema. 
Her past medical history was significant for a pulmonary 
embolism at the age of 18, treated with warfarin, multiple 
episodes of pneumonia from 1999 to 2007, and a 
diagnosis of superior vena cava (SVC) syndrome in 2008. 
Her social history was significant for a 10 pack year history 
of cigarette smoking. Her family history was significant for 
her father with myocardial infarction at age 50. 
On her most recent physical exam her vitals were 
temperature 99.1°F, blood pressure 110/82 mm Hg, pulse 
Figure 1: SVC occlusion with dense calcification suggestive of 
chronic inflammatory or post-radiation etiology
Figure 2. Calcified granuloma. Ground glass opacity of right 
upper lung. Loss of volume of right upper lung
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of 72 beats per minute, and oxygen saturation of 97% 
on room air. She was without cervical lymphadenopathy 
and lacked neck or face swelling. Her lungs were clear 
to auscultation, and auscultation of her heart revealed 
regular rate and rhythm and normal heart sounds with 
no murmurs, rubs or gallops. There was no cyanosis, 
clubbing or edema of the extremities. Her skin exam was 
notable for prominent veins of the upper chest wall and 
dilated tortuous abdominal wall veins.
SVC syndrome was diagnosed in 2008 
when she presented to her primary 
care provider with left neck swelling. 
CT of her neck at the time showed a 
heterogeneous density in the left external 
jugular vein which was thought to be a 
thrombus; however, upper and lower 
extremity Dopplers were negative for 
acute thrombus. Further evaluation with 
CT of her chest with contrast showed 
SVC occlusion with dense calcification, 
suggestive of chronic inflammatory or 
post-radiation etiology (Figure 1). The 
patient, however, denied any history of 
radiation exposure or central vein catheter-
ization. Interestingly, the CT of the chest 
also showed a chronic calcified occlusion 
of the right upper lung (RUL) pulmonary 
artery. She also had RUL ground-glass opacities with a 
calcified granuloma (Figure 2), and calcified mediastinal 
and hilar nodes, prominent venous collateral formation 
in the chest wall and mediastinum, and calcifications of 
her spleen (Figures 3,4).
DiFFErEnTial DiagnoSiS
Bronchoscopy performed to further evaluate her 
abnormal CT findings in her lungs was largely 
unrevealing. Tissue biopsy was negative for 
malignancy and sputum stained negative for acid-fast-
bacilli (AFB). Fungal, AFB and respiratory viral cultures 
were also negative. Rheumatologic workup, including 
antinuclear antibody (ANA), perinuclear anti-neutrophil 
cytoplasmic antibodies (p-ANCA), cytoplasmic-ANCA 
(c-ANCA), and rheumatoid factor (RF) were negative.
Given the CT imaging which showed calcified 
mediastinal lymph nodes and calcified occlusions 
of the SVC and RUL pulmonary artery, as well as 
thick fibrotic tissue in the mediastinum, the patient 
was diagnosed with fibrosing mediastinitis (FM). FM 
is a radiologic diagnosis. Etiologies in North America 
include histoplasmosis (82%), idiopathic (18%), and 
Mycobacterium tuberculosis or other mycoses.1
Figure 3: A. Narrow SVC B. Calcified mediastinal lymph node C. Dilated azygous vein. 
Figure 4: A. Dilated chest wall collaterals. B. Calcified SVC and 
hilar lymph node. C. Splenic calcifications.
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H. capsulatum is endemic to the Ohio and Mississippi 
River Valleys with several microfoci in Mid-Atlantic 
States, Africa, Southeast Asia, and Europe. The 
dimorphic fungus exists as a mold in the soil and as 
a yeast at 37°C. Nitrogen-rich soil from bird and bat 
excrement enhances the growth of H. capsulatum. 
The mold is easily aerosolized and inhaled. Once in 
the lungs it is phagocytized by macrophages.4 The 
severity of illness depends on the amount of inoculum 
and host immune response. Over 80% of young adults 
from the Ohio and Mississippi River Valleys have been 
exposed, as evidenced by positive skin antigen testing. 
In most cases, patients have no symptoms or a very 
mild pneumonia-like illness that resolves on its own 
within four weeks. Acute exposure to a large amount 
of inoculum or severe immunosuppression can result 
in severe pneumonitis and respiratory failure.5
While most symptomatic infections with H. capsulatum 
have acute pulmonary manifestations, ~1% of patients 
have extra-pulmonary manifestations, including 
pericarditis, rheumatologic syndromes (arteritis, 
erythema nodosum), mediastinal lymphadenitis, 
progressive disseminated histoplasmosis, and 
mediastinal fibrosis.5
Mediastinal fibrosis is a rare complication of Histoplasma 
infection, and it is not known why <1% of patients 
exposed to the mold develop FM.6 One widely accepted 
hypothesis for the pathophysiology includes leakage of 
fungal antigen from the infected lymph nodes in the 
mediastinal space resulting in a delayed hypersensitivity 
reaction.7 Another hypothesis proposes that rupture 
of a caseous lymph node from a primary infection 
invokes an inflammatory reaction and subsequent 
fibrosis.2 Fibrosing mediastinitis is also thought to be an 
abnormality of collagen production and organization, 
akin to idiopathic retroperitoneal fibrosis and on the 
spectrum of IgG4-related disease.8 Genetic host factors 
may play a role as there is a slight predominance of 
women with the disease.4
During this chronic disease process, excess collagen 
production entraps mediastinal structures and causes 
subsequent symptomatology. Most patients present 
with nonspecific symptoms of chest pain, cough and 
dyspnea. Only ~20% of patients progress to severe 
occlusion of great vessels or airways.5 Obstruction of 
pulmonary arteries often results in symptoms of right 
ouTcoME anD Follow-uP
The patient is followed annually for her fibrosing 
mediastinitis. The latest CT thorax performed in 2012 
showed ground-glass opacities and loss of volume 
in the RUL with traction bronchiectasis. She also had 
new narrowing of the right superior pulmonary vein in 
addition to the chronic occlusion of the RUL pulmonary 
artery. Her imaging also showed dilated azygous and 
hemiazygous veins and extensive anterior chest wall 
venous collaterals that have increased in diameter over 
the last three years.
DiScuSSion
Fibrosing mediastinitis (FM) is a chronic form of 
mediastinitis that is characterized by invasive fibrosis 
that compresses and encases mediastinal structures, 
including lymph nodes, central vessels, and airways. FM 
is diagnosed by radiological findings of calcifications 
of hilar and mediastinal lymph nodes and evidence 
of fibrotic tissue within the mediastinum. While the 
pathophysiology of fibrosing mediastinitis is poorly 
understood, it is believed that most cases in North 
America are due to Histoplasma capsulatum.1 About 
80% of patients with FM present with radiographic 
or serologic evidence of Histoplasmosis infection 
or exposure.2 Rare case reports have also described 
fibrosing mediastinitis secondary to tuberculosis and 
other fungal infections, including blastomycosis, 
coccidiomycosis and aspergillosis.3 In about 18% of 
patients, no infectious cause is identified and the 
etiology is thus labeled as idiopathic. Other conditions 
that mimic the radiological findings of FM include 
sarcoidosis, mesothelioma, idiopathic retroperitoneal 
fibrosis, and radiation-associated mediastinal fibrosis. 
The most likely etiology of this patient’s FM is 
histoplasmosis, as she presented with radiological 
evidence of prior histoplasmosis infection, including 
the characteristic mediastinal granuloma and splenic 
calcifications. She is also from an area endemic to 
H. capsulatum. It is likely that her FM was secondary 
to histoplasmosis even in spite of her urine antigen 
testing for histoplasmosis being negative, as only 
~10% of patients with chronic lesions have positive 
antigen testing, and patients with chronic forms of 
histoplasmosis such as FM generally do not have 
positive urine antigen testing.1 The urine antigen testing 
is most useful in acute pulmonary histoplasmosis with 
large inoculum or disseminated histoplasmosis. 
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KEy PoinTS
In summary, fibrosing mediastinitis is a rare disease and 
a rare complication of histoplasmosis. The majority of 
adults in the Ohio River Valley have fungal exposure; 
however, only a small number of people with prior 
Histoplasma infection develop FM. Most patients with 
FM have a self-limited course of fibrosis, however some 
progress to fatal occlusion of great vessels.
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heart failure. Airway obstruction will cause recurrent 
episodes of bronchitis or pneumonia in addition to 
wheezing, cough and dyspnea. Some patients will have 
difficulty swallowing secondary to posterior extension 
of the fibrosis entrapping the esophagus.2 The extent 
of invasion and obstruction is best visualized with CT 
imaging and angiography, although MRI has also been 
used.4
There is no known treatment for fibrosing mediastinitis. 
No controlled trials of medical or surgical therapy 
have been conducted. Antifungal or anti-inflammatory 
treatment with corticosteroids is not indicated as this is 
a disease primarily of enhanced collagen deposition.5 
Placement of intravascular stents has been helpful 
in patients with vascular stenosis for symptomatic 
management. In one report, percutaneous stenting in 
pulmonary arteries or SVC showed effective short-term 
and mid-term success in improving vascular patency 
of six study patients; however, in-stent re-stenosis 
was a frequent complication and progressive fibrosis 
remained a clinical problem.7 Thankfully, many patients 
have a self-limited course of fibrosis. In a retrospective 
study of 80 patients, most patients had a survival similar 
to age-matched controls.3 
In our patient, her symptomatology can be directly 
related to FM. Her lightheadedness on standing is likely 
from poor filling pressures of her right atrium from 
chronic SVC occlusion. She also has pulmonary vein and 
pulmonary artery stenosis, contributing to her dyspnea 
and easy fatigability. Her recurrent pneumonias are 
also likely explained by airway obstruction. Significant 
physical exam finding of large superficial veins are 
evidence that her body is compensating for the fibrotic 
and obstructive process in her thorax by forming 
collateral blood flow. Evidence of collateral blood 
flow is also evident in CT imaging showing enlarged 
azygous and hemiazygous veins (Figure 3). Her 
radiographic imaging strongly points to histoplasmosis 
as the etiology of her FM. At the time of this case 
report’s authoring, she did not show hemodynamic 
compromise requiring intravascular stenting; although, 
this is a therapeutic option to consider in the future if 
her disease progresses. She is currently being treated 
with narcotics and gabapentin for pain control.
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HIV Screening: A Review of Nationally 
Recommended Guidelines and Specific Instances 
in which HIV Screening is Often Overlooked 
Anusha Ganesh, MD
inTroDucTion
According to the Centers for Disease Control and 
Prevention (CDC), one in five human immunodefi-
ciency virus (HIV)-infected individuals are currently 
living without knowledge of their diagnosis.1 In 2006, 
the cost of a rapid HIV test with pre/post-test HIV 
counseling was anywhere between 48-64 US dollars 
(USD). The majority of the cost incurred was for 
HIV counseling, with the cost of the rapid HIV test 
being between 8-25 USD.2 Research looking at the 
cost-effectiveness of HIV screening shows that it is 
more cost-effective than routine screening for breast 
cancer with mammography yearly or even routine 
screening for diabetes mellitus with a one-time fasting 
blood glucose.3 With the cost of testing reasonably 
low and prevalence of undiagnosed infection high, 
why are our rates of HIV screening not maximized?
caSE PrESEnTaTion
The following is an example of a patient who would 
have benefitted from HIV screening as per national 
guidelines. Ms. C is a 48-year-old female who 
presented at her gynecologist’s office for a routine 
examination and PAP smear. The patient had never 
been offered HIV screening in the past. She had 
a positive HIV test at that visit and was sent to the 
Infectious Disease clinic for follow-up care. Ms. C 
denied any active symptoms. Her past medical and 
surgical history included syphilis, treated with a short 
course of penicillin G, lower back pain, depression, 
hypothyroidism, gastroesophageal reflux disease 
(GERD), asthma, tubal ligation, and lipomectomy. She 
has had multiple Emergency Department (ED) visits in 
the last three years for various unrelated complaints. 
Yearly mammograms had been performed for health 
maintenance and were all within normal limits. She 
denied history of tuberculosis, pneumonia, or other 
opportunistic infections. Her social history was 
positive for a history of non-intravenous drug use in 
the past and tobacco abuse. She had no recent travel 
and no current HIV risks or exposures. She has been 
married for twenty years and stated that she was 
sexually active and monogamous with her husband. 
Her vital signs were within normal limits, and there 
were no abnormalities noted on physical exam.
Based on national guidelines, her positive HIV 
enzyme immunoassay (EIA) screen was followed by 
a confirmatory HIV Western Blot.4 Her baseline HIV 
viral load was 1090 copies/mL, and her CD4 count 
was 230 cells/µL. Although this patient had been 
treated in the ED numerous times, she remained 
compliant with health maintenance and had surgical 
procedures. However, she had never been screened 
for HIV. Screening for HIV at any of these points in 
time may have led to earlier diagnosis and treatment.
Broad screening is important, as earlier treatment 
of HIV has been studied compared to deferred 
treatment and has been shown to increase survival.5 
A study compared the risk of death in patients who 
were started on anti-retrovirals at a higher vs. lower 
CD4 counts. Those started with the higher CD4 
count had improved outcomes with a reduction 
in number of deaths. Studies have also shown that 
the risk of transmission of HIV is directly related to 
viral load, which can be treated if addressed sooner.6 
The patients who are generally screened are "high 
risk" patients, such as people who engage in sex 
without protection, sharing of drug-use equipment, 
occupational hazards, men who have sex with men, 
and youths.7
This paper will review the current HIV screening 
guidelines from multiple national organizations 
(Table 1), which emphasize the importance of screening 
those individuals who are not necessarily "high risk".
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DiScuSSion
inpatient
In 2010, a study was conducted at the Veterans Affair 
Hospital in Washington, D.C. which looked at the 
percentage of patients accepting routine HIV screening 
in the hospital. Until 2010, only those patients who 
were considered "high risk" were tested. The testing 
rate increased from 4.25% (high risk only) in previous 
years to 23.8% (all patients offered screening) during 
this trial.8 A similar study performed in New York City in 
2005 showed that, of the patients who were asked to 
participate in HIV testing, there was not a significantly 
higher percentage who carried traditional risk factors 
for HIV. The study supported routine, voluntary 
testing for HIV, as it diagnosed patients who were not 
identified in the risk-based testing.9 The CDC studied 
physician-referred HIV testing rates compared to HIV 
testing rates when a “Voluntary HIV Counseling and 
Testing” (VCT) program was implemented, allowing 
all patients to be queried about HIV testing. This 
program tripled the number of patients being tested 
for HIV daily.10 All these studies validate the argument 
that, if offered routinely, the utilization of inpatient HIV 
screening would rise significantly, capturing those who 
may not be routinely followed in a primary care setting. 
The Emergency Department has been cited by the CDC 
as an important location in which patients of a lower 
socioeconomic status have their first interaction with 
a physician. The CDC has recommended in its 2001 
guidelines that ED-based HIV testing and counseling 
should be more widely implemented.11 In one study, 
targeted screening was studied in a Midwestern, urban 
teaching hospital to determine the cost-benefit and 
higher true positive rate of testing of high-risk patients 
in the ED versus opt-out testing for all patients. The 
study deemed that, with a wider testing population, 
more positive tests were identified with a proportional 
increase in tests offered. There was no benefit to 
targeted screening, as it did not have a proportionately 
higher number of positive test results when compared 
to the large screening group.12
Table 1: HIV Screening Recommendations 
Organization Screening recommendations Notes
CDC15 anyone ages 13-64 regardless of risk
high risk patients annually
all pregnant women
repeat in third trimester for all high 
risk pregnant women
infants exposed in utero
victims of sexual assault
opt out method: allow patient to decline
preventative counseling for HIV not required
written consent not required
United States Preventative 
Services Task Force 
(USPSTF)16
anyone ages 15-6
younger adolescents and older 
adults who are at risk
all pregnant women, including 
those who present in labor
American College of 
Physicians (ACP)17
all patients once, more often for 
those "at risk"
“at risk”: shared injection drug use, blood transfusion 
between 1978-1985, unprotected sex with multiple 
partners, having an STD
American Academy of HIV 
Medicine (AAHIVM)18
all adults over 15
all adults over 65 (aren’t these the 
same thing?
opt out testing
American College of 
Gynecology (ACOG)19
all women between 19 and 64
women with risk factors outside 
that age range 
opt out testing
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The Elderly
It is becoming increasingly important to address HIV 
screening in the elderly population who are often 
not considered candidates for testing, as safe sexual 
practices are not always comfortably discussed in this 
population.13 Among all patients with HIV infection, 37% 
are now over the age of fifty. It is estimated that this 
number will increase to 50% by the year 2015.13 Patients 
who are diagnosed at a later age will be more likely 
to experience increased morbidity and mortality and a 
higher risk of opportunistic infections.13 The main risk 
factor for HIV acquisition in the elderly is heterosexual 
intercourse.13 The reasons for missed opportunities 
for HIV screening in this population include lack of 
knowledge of HIV in older patients, underestimating the 
risk of contracting HIV, and the social stigma associated 
with HIV.13
low risk Factor Population 
In 2006, the Institute of Medicine (IOM) studied 
offers of HIV screening to patients in the state of 
Virginia. IOM discovered that primary care physicians, 
although aware of the guidelines, were more hesitant 
to implement screening in all patients because they 
weren’t comfortable treating patients who had a 
positive test result.14 HIV testing also required more 
staffing and education to providers in the clinic. Further 
complicating this was the difficult conversation with 
individuals, such as our patient, who are not considered 
to be "high risk".14 Nonetheless, the evidence shows that 
even in low risk populations, it is vital for primary care 
providers to address the importance of a one-time HIV 
screening to ensure the patient’s health and safety. 
KEy PoinTS
The three main categories of patients who are often 
missed for HIV testing include patients in the acute 
care setting, elderly individuals, and the low-risk 
population. They should all be offered opt-out testing 
by their primary physician or hospitalist, as per national 
guidelines. It is a low-cost test, with an extremely high 
benefit value. All major national health organizations 
are recommending that physicians offer one time HIV 
screening in all patients regardless of age, gender, or 
perceived risk status. 
35
et al.: Download entire issue of The Medicine Forum, Volume 15, 2013-2014
Published by Jefferson Digital Commons, 2015
34   |  The Medicine Forum     5
19. Routine Human Immunodeficiency Virus Screening. ACOG 
Opinion No 411. American College of Obstetrics and Gynecology 
2008. (Accessed November 1, 2013, at http://www.acog.org/
Resources_And_Publications/Committee_Opinions/Committee_
on_Gynecologic_Practice/Routine_Human_Immunodeficiency_
Virus_Screening)
17. Qaseem A, Snow V, Shekelle P, et al. Screening for HIV in health 
care settings: a guidances statement from the American College 
of Physicians and HIV Medicine Association. Annals of Internal 
Medicine. 2009; 150(2): 125-131.
18. Routine HIV Testing. American Academy of HIV Medicine, 2013. 
(Accessed November 1, 2013, at http://www.aahivm.org/routine-
hivtesting.)
"Japanese Maple, Longwood Gardens” 
photograph by Andrew Zabolotsky, MD
36
The Medicine Forum, Vol. 15 [2015], Art. 29
http://jdc.jefferson.edu/tmf/vol15/iss1/29
 The Medicine Forum  |   35 5
Fever in a Man with HIV: An Unusual Case  
of an Immune System Gone Wrong
Emily Sutton, MD, Aishah Ali, MD
inTroDucTion
Hemophagocytic lymphohistiocytosis (HLH) is a rare 
syndrome of immune dysregulation that is often 
recognized as secondary to an underlying immune 
activating state, such as malignancy, rheumatologic 
disorders, and infections. This case highlights an 
association between HLH and human immunodefi-
ciency virus (HIV) infection. Although HLH is a rare 
complication of HIV, it presents a difficult challenge for 
treatment. Without treatment, HLH is invariably fatal, but 
the consequence of the immunosuppressive treatment 
regimen in the setting of an underlying opportunistic 
infection can also have fatal outcomes. 
caSE PrESEnTaTion
A 38 year-old man with a history of HIV infection with a 
CD4 lymphocyte count of 2 cells/mm3 presented with 
fevers two weeks after starting antiretroviral therapy 
(ART). His initial extensive infectious workup was 
negative, including cryptococcal antigen in the serum 
and cerebrospinal fluid. His liver enzymes then began 
to rise, prompting concern for drug toxicity. At this 
time, ART and trimethoprim/sulfamethoxazole were 
discontinued, but he continued to have high-grade 
fevers as well as hypotension, pancytopenia and 
hypofibrinogenemia and was transferred to the medical 
intensive care unit (MICU). On admission to the MICU, he 
was febrile with a temperature of 103.6°F, hypotensive 
with a blood pressure of 78/37 mmHg, tachycardic with 
a heart rate of 127 beats per minute, tachypneic with a 
respiratory rate of 26 breaths per minute, and had an 
oxygen saturation of 97% on room air. On exam, he 
was thin, in moderate distress, and lethargic. He had 
no thrush or nuchal rigidity. He had cervical lymphade-
nopathy and hyperpigmented maculopapular rashes 
on his lower extremities; otherwise his exam was 
unremarkable. 
DiFFErEnTial DiagnoSiS
The differential diagnosis included opportunistic 
infections given his CD4 count of 2 cells/mm3, immune 
reconstitution inflammatory syndrome (IRIS) given his 
Figure 1: The patient’s bone 
marrow biopsy demonstrating 
hemophagocytosis of platelets 
(short arrow) and erythrocytes 
(long arrows).
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recent initiation of ART, drug reaction or toxicity, and 
hemophagocytic lymphohistiocytosis (HLH). Further 
laboratory studies revealed an elevated ferritin level of 
83,987 ng/mL (normal range = 30-400), which was 
highly suspicious for HLH. The diagnosis was confirmed 
with a bone marrow biopsy revealing hemophagocytosis 
(Figure 1) as well as an elevated interleukin 2 receptor 
(IL2R) level of 9020 pg/mL (normal range = 0-1033). 
ouTcoME anD Follow-uP
The patient was treated with intravenous immuno-
globulin, high dose dexamethasone, and anakinra, 
an IL1R inhibitor, resulting in cessation of his fevers, 
resolution of his respiratory distress, and improvement 
in his cell lines. He was transferred back to the floors 
with plans to restart ART. As no underlying infection had 
been found, his HLH was thought to be secondary to 
his HIV infection. However, three days later, he became 
acutely short of breath and hypotensive and was found 
to have Cryptococcus neoformans fungemia, although 
his initial blood and cerebrospinal fluid fungal studies 
were negative. He was transferred back to the MICU, 
initiated on intravenous amphotericin B/flucytosine, 
and ART was discontinued. However, he continued to 
decompensate rapidly and expired from septic shock 
and acute pulmonary edema later that day.
DiScuSSion
Hemophagocytic lymphohistiocytosis (HLH) is a severe 
and rapidly progressive disorder of immune activation 
and dysregulation that can occur as a familial disorder 
or, as is becoming increasingly recognized, secondary 
to a variety of underlying conditions. Secondary HLH 
occurs after strong immunologic activation, such as 
with severe infection, immunodeficiency, or underlying 
malignancy. In the past, HLH was also sometimes 
referred to as hemophagocytic syndrome. Another 
disorder on the spectrum of this disease state includes 
macrophage activation syndrome, which is a form of 
HLH associated with rheumatologic diseases.1 Although 
the immune cells in HLH are functionally normal, it is 
thought to be the result of proliferation of activated T 
cells that go on to activate macrophages, as well as 
the lack of appropriate apoptosis of immunogenic cells. 
As these overly active macrophages and histiocytes 
proliferate and run rampant, they phagocytize other 
cells, including erythrocytes, leukocytes, and platelets, 
leading to the clinical symptoms. This highly stimulated 
immune system results in life-threatening cytokine 
storm and inflammatory reactions.1,2 
As the clinical entity of HLH is a syndrome, it has 
features that can be seen in other clinical states, but it 
is the combination of findings that make the diagnosis 
likely. The diagnostic criteria for HLH include fever, 
splenomegaly, cytopenia of at least 2 of 3 cell lines, 
elevated ferritin, hypofibrinogenemia and/or hypertri-
glyceridemia, elevated CD 25 (IL-2 receptor), low or 
absent natural killer (NK) cells, and hemophagocytosis 
seen in the bone marrow, liver, spleen, or lymph nodes. 
Five of these eight criteria must be met in order to 
establish the diagnosis (Table 1).3 Notably, the criteria 
only require a ferritin level >500 ng/mL, but a level 
>10,000 ng/mL is thought to be highly suspicious for 
HLH, with a specificity of 96%.4 The ferritin level upon 
diagnosis has also been found to have prognostic value, 
and its decline correlates with response to treatment. 
The soluble IL-2 receptor was found to be a more 
sensitive marker than ferritin with a sensitivity of 93% 
and also carries prognostic implications.5 
Table 1: Diagnostic Criteria for HLH3
Diagnosis of HLH requires
Molecular diagnosis consistent with HLH 
-OR-
Fulfillment of 5 of the 8 criteria listed below:
1. Fever > 38.5C
2. Splenomegaly
3.  Cytopenias (affecting at least 2 of 3 lineages 
Hemoglobin < 9 g/dL 
Platelets < 100 x 103/mL 
Neutrophils < 1 x 103/mL)
4.  Hypertriglyceridemia (fasting > 265 mg/dL) and/or 
hypofibrinogenemia (< 150 mg/dL)
5.  Hemophagocytosis in bone marrow, spleen, lymph 
nodes, or liver
6. Low or absent NK-cell activity
7. Ferritin > 500 ng/mL
8. Elevated sCD25 (α-chain of sIL-2 receptor)
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Patients presenting with a clinical picture of fever and 
highly elevated inflammatory markers should raise the 
suspicion for hemophagocytic lymphohistiocytosis 
(HLH). Five of the eight criteria must be met for the 
diagnosis, but a ferritin level >10,000 ng/mL is highly 
suspicious. HLH is fatal without treatment, but immuno-
modulatory therapy directed at HLH may be perilous in 
the setting of underlying infection. Currently, there are 
no guidelines on empiric antibiotic use for patients with 
HIV and HLH, but one must be vigilant in searching for 
underlying infections given the risk of the immunosup-
pressive regimen required to treat HLH in the setting 
of HIV. 
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Without therapy, HLH is uniformly fatal. Treatment 
includes supportive care, immunomodulatory therapy, 
and treatment of any underlying condition. For the 
familial form of HLH, the treatment backbone is an 
induction phase involving chemotherapy, typically 
etoposide, combined with immunotherapy, such 
as cyclosporine A and steroids. This is followed by a 
continuation phase that is to be maintained until stem 
cell transplant is available, as transplant is the only 
curative treatment for familial HLH. The treatment for 
secondary HLH is not as well defined as it can vary based 
on the associated disease. For underlying malignancies, 
the treatment approach is often similar to the familial 
form, with chemotherapy and immunotherapy. For 
the secondary forms associated with immunodefi-
ciency or rheumatologic causes, the approach relies 
more heavily on immunomodulators, such as the IL-1 
receptor antagonist anakinra.2
In the context of HIV, HLH has been reported to occur 
secondary to opportunistic infections, as well as from 
HIV infection itself, both during the acute serocon-
version phase and the profoundly immunosuppressed 
state.6,7 Given the non-specific clinical manifestations 
of HLH and the otherwise heightened concern for 
opportunistic infections, one must have a high clinical 
suspicion for recognizing this disease in the setting of 
HIV. Treating HLH in the setting of severe immunosup-
pression from HIV presents a difficult challenge, as with 
this patient. As induction treatment for HLH requires 
high dose steroids and IV immunoglobulin to quell 
the life-threatening inflammatory response, underlying 
opportunistic infections may prove to be fatal if they 
go unrecognized. There are no current guidelines on 
antibiotic use in HIV patients with confirmed HLH, and 
it may be of value to treat these patients empirically for 
opportunistic infections in the setting of critical illness. 
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with definitive coronary artery bypass graft surgery 
within 24-72 hours. Due to persistent hypotension, 
an intra-aortic balloon pump was placed with good 
diastolic augmentation. 
DiFFErEnTial DiagnoSiS
At this point, the differential diagnosis for the patient’s 
decompensation included cardiogenic shock secondary 
to left or right heart failure, rhythm disturbances such as 
complete heart block, and mechanical complications. 
The three main mechanical complications to consider 
in the setting of acute hypotension with an acute 
myocardial infarction include papillary muscle rupture 
causing acute mitral regurgitation, ventricular free wall 
rupture, and ventricular septal defect.
During this event, the patient did not demonstrate any 
new heart block on ECG monitoring. Thus, mechanical 
causes of her acute hypotension were investigated. 
Contrast ventriculography has the benefit of evaluating 
left ventricular function as well as illustrating possible 
free wall rupture, acute mitral regurgitation, or any 
new VSD. In this case, contrast ventriculography was 
performed revealing a large ventriculoseptal defect 
(VSD) in the inferoseptal wall (Figure 3). 
Post-procedure transthoracic echocardiogram 
confirmed inferoseptal VSD and found a contiguous 
partial myocardial tear of the inferior wall with pseudoa-
neurysm (Figure 4). Given the high mortality of VSD and 
impending rupture of the inferior free wall, the patient 
was taken for operative cardiac repair.
ouTcoME anD Follow-uP
In the case of this patient, the initial plan during her 
cardiac catheterization was to revascularize her culprit 
lesion (the RCA) and then ultimately pursue bypass 
surgery given her multivessel disease. However, after 
inTroDucTion
This is a case of acute ventricular septal defect (VSD) 
that was diagnosed while a patient with an acute 
ST-elevation myocardial infarction (STEMI) was being 
treated in the cardiac catheterization laboratory. 
Post-MI VSD is a well-recognized complication of 
STEMI, and this case was particularly interesting given 
the circumstances of its diagnosis. 
caSE PrESEnTaTion 
A 75 year-old female with a history of well-controlled 
hypertension presented with 3 days of substernal 
chest pain radiating down her left arm. The pain was 
severe, unremitting, associated with shortness of breath, 
nausea, vomiting, and was not relieved by simethicone 
or by changes in position. The patient had a blood 
pressure of 165/92 mmHg, heart rate of 104 beats per 
minute, and physical examination was unremarkable. 
The initial electrocardiogram (ECG) showed 1mm ST 
elevations in the inferior leads (Figure 1). ECGs taken 
1 hour later showed an increase in the inferior ST 
elevations to 2-3mm, and troponin T was elevated 
to 2.36ng/mL (normal range = <0.01ng/mL) (Figure 
2). Echocardiogram showed inferior and inferoseptal 
akinesis as well as decreased left ventricular systolic 
function with an ejection fraction of 30%.
The patient was admitted for STEMI, given a full 
dose aspirin and atorvastatin, started on eptifibatide 
infusion, unfractionated heparin infusion, and taken 
for cardiac catheterization. At this time, her blood 
pressure remained elevated, so she was started on 
a nitroglycerin infusion. Subsequently, she became 
profoundly hypotensive, and the nitroglycerin infusion 
was discontinued. Coronary angiography showed right 
dominant coronary circulation with total thrombotic 
occlusion of the distal right coronary artery (RCA) 
and severe multivessel disease. Balloon angioplasty 
of the RCA was performed, with the plan to proceed 
Interventricular Septum Rupture in the 
Catheterization Laboratory
Xing Zhang, MD, Loheetha Ragupathi, MD
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Figure 1: Initial ECG showing 1mm ST elevations in inferior leads
Figure 2: ECG taken 1 hour after presentation showing increase in inferior ST elevations to 2-3mm
her VSD was diagnosed, she had a balloon pump 
placed and she was taken emergently to the OR with 
successful repair of her defect. Unfortunately, after her 
procedure, she required significant vasopressor and 
inotropic support. She also developed and remained 
in complete heart block. After a week of aggressive 
medical therapy, her family ultimately elected to 
withdraw care.
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Diagnosis can be made in several ways. The gold 
standard remains insertion of a pulmonary artery balloon 
catheter which demonstrates a significant left to right 
shunt. Giant pulmonary capillary pressure V-waves may 
also occur secondary to volume overload and reduced 
atrial and ventricular compliance.6 Two dimensional 
transthoracic echocardiogram can also visualize the 
defect directly. This ability is significantly enhanced 
with the use of color Doppler imaging, and one study 
DiScuSSion
While ventricular septal rupture is a well described 
complication of acute myocardial infarction, this case 
is relatively unique in that the diagnosis was made in 
the cardiac catheterization laboratory with the aid of 
contrast ventriculography. The incidence of VSD has 
decreased significantly after the advent of reperfusion 
therapy, from 2% of cases of infarction to as low as 
0.2% described in the GUSTO trial.1 However, it remains 
a problem with very high morbidity and mortality, 
especially in the setting of cardiogenic shock, as in 
this patient. It remains uniformly fatal without surgical 
intervention. This case helps highlight the importance 
of early and immediate recognition of VSD in 
facilitating emergency surgical repair. It also illustrates 
the importance of keeping VSD in the differential of 
acute hypotension during management of an acute 
myocardial infarction in the cardiac catheterization 
laboratory and the use of contrast ventriculography in 
making the diagnosis. 
Ventricular septal rupture tends to occur 3 to 5 days 
after a myocardial infarction; however, cases have been 
described as recent as within 24 hours of an MI. Notably, 
this patient’s initial MI was most likely 3 days prior to 
presentation to the ER. Risk factors include single vessel 
disease of the left anterior descending artery, advanced 
age, female sex, myocardial damage, massive MI, 
and poor septal collateral circulation.2 In particular, 
patients with a “wrap-around” left anterior descending 
(LAD) appear to have an elevated risk. In the majority 
of individuals, the inferior third of the interventricular 
septum is supplied by the RCA; however, in some 
individuals the LAD extends beyond the apex, wrapping 
around to supply the inferior septum. Thus, these 
patients tend to have a higher risk of septal rupture in 
the setting of a STEMI, and ECG changes often show 
both anterior and inferior ST elevations.3
Patients present with hemodynamic compromise 
caused by biventricular failure, as well as a new harsh, 
holosystolic murmur heard best at the lower left and 
right sternal borders.4 Patients may also have a palpable 
thrill and a hyperdynamic precordium. Among patients 
who are not reperfused, such as this patient, septal 
rupture is often associated with persistent ST elevation 
for greater than 72 hours.5 
Figure 3: Contrast ventriculography showing a defect in the 
inferior wall of the left ventricle.
Figure 4: Parasternal short axis view with Doppler showing flow 
through the inferoseptal wall consistent with ventricular septal 
rupture 
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demonstrated that adding color Doppler improved the 
visualization of the VSD from 40% to 100%.7 While left 
ventriculography can also be used to document the 
presence of the shunt, as in our patient, it tends to 
be unnecessary. However, with our patient presenting 
with acute cardiogenic shock while undergoing cardiac 
catheterization, it proved invaluable.
In patients presenting with frank cardiogenic shock, 
emergent surgery is required to prevent imminent 
death. Acute medical management involves afterload 
reduction with vasodilators and intraaortic balloon 
pump, which decreases the left to right shunt. Inotropic 
agents may also be used to increase cardiac output. 
Notably, several studies have also demonstrated that 
full revascularization of patients during operative repair 
of their VSD with bypass surgery also improves long 
term mortality.8, 9 Novel approaches are also being used, 
such as percutaneous closure in patients with contrain-
dications to bypass surgery. However, long-term study 
outcomes of this procedure are currently unavailable.
"The Amalfi Coast” 
photograph by Michael Valentino
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Anomalous Left Main Coronary Artery Originating 
from the Right Sinus of Valsalva
Silpa Yalamanchili, MS IV, Kevin M Curl, MD
inTroDucTion
An anomalous left main coronary artery is a rarely 
seen clinical entity, particularly when it arises from the 
right sinus of Valsalva. This case report highlights this 
uncommon finding and how it affects the care of a 
patient with significant coronary artery disease.
caSE PrESEnTaTion
A 66 year-old male with a history of hypertension, 
hyperlipidemia, and type II diabetes presented with 
progressive exertional mid-epigastric and mid-chest 
discomfort. The patient stated that he had been feeling 
this “heaviness” with various activities and occasionally 
at rest for the past nine months. When it occurred with 
activity, the pain was generally relieved by rest within 
several minutes. His medications on presentation 
included insulin glargine, glyburide, metformin, 
simvastatin, pioglitazone, and lisinopril. Vital signs at the 
time of presentation included a temperature of 98.2°F, 
heart rate of 82 beats per minute, and blood pressure of 
130/70 mmHg in both arms. 
Laboratory investigation showed a total cholesterol of 
178 mg/dL (normal range = 150-250), high-density 
lipoprotein (HDL) cholesterol of 42 mg/dL, low-density 
lipoprotein (LDL) cholesterol of 111 mg/dL, triglycerides 
of 123 mg/dL, and hemoglobin A1C of 7.9% (normal 
range = <5.7%). Pharmacologic nuclear stress testing 
revealed a severe, medium sized defect in the 
inferolateral wall that was predominately reversible. 
Thus, the patient underwent a cardiac catheterization 
which revealed an anomalous left main (LM) coronary 
artery arising from the right sinus of Valsalva separately 
from the origin of the right coronary artery (RCA). The 
distal left anterior descending artery (LAD) had a total 
occlusion, while the RCA had several areas of 70% 
stenosis. A subsequent coronary CT scan displayed an 
anomalous left coronary artery coursing anterior to the 
Figure 1. Coronary CT scan showing the separate origins of 
both the RCA (vertical arrow) and LM (horizontal arrow) from 
the right sinus of Valsalva.
Figure 2. 3D coronary CT scan reconstruction again 
demonstrating dual origins of the RCA (vertical arrow) and LM 
(horizontal arrow) from the right sinus of Valsalva.
pulmonary artery (Figures 1, 2). The CT scan also showed 
moderate to high grade RCA stenosis in the mid to distal 
area of the vessel, as well as high-grade stenoses in the 
small-sized LAD and left circumflex arteries.
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Diagnostic evaluation of asymptomatic patients in which 
an anomalous LM is suspected is currently indicated 
only for those at highest risk of sudden cardiac death: 
young athletes and military personnel. In patients 
who present symptomatically, CT angiography is able 
to detect coronary anomalies nearly as effectively as 
coronary angiography.5
Symptomatic patients or young athletes with anomalous 
LM typically warrant surgical intervention, either by 
local repair of the anomalous segment or by coronary 
artery bypass and graft (CABG).5 Other treatment 
options in these patients include medical management 
with beta blockers or coronary angioplasty with stent 
deployment.
KEy PoinTS
Anomalous left main coronary arteries, although rare, 
can complicate the care of patients with clinically 
significant obstructive coronary artery disease.
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ouTcoME anD Follow-uP
This management of this patient is currently being 
discussed by a multidisciplinary team including his 
primary care provider, clinical cardiologist, interventional 
cardiologist and a cardiothoracic surgeon.  It is felt that 
his anomalous coronary artery was an incidental finding 
and his uncontrolled medical co-morbidities have led 
to significant obstructive coronary disease causing his 
symptoms.  Thus, aggressive medical management 
has been implemented while the patient’s long term 
options are being reviewed, with a significant focus on 
tighter diabetic and lipid control.
DiScuSSion
An aberrant left main coronary artery originating 
from the right sinus of Valsalva is an extremely rare 
occurrence, with an incidence of 0.06% to 0.19% by 
angiographic study.1 In such cases, the anomalous LM 
is classified into one of four categories based on its 
course in relation to the aorta and pulmonary trunk: 
(1) posterior or retroaortic; passing behind the aortic 
root, (2) interarterial or preaortic; passing between the 
aorta and pulmonary trunk, (3) anterior or prepulmonic; 
passing in front of the pulmonary trunk, or (4) septal or 
subpulmonic; passing within the interventricular septum, 
beneath the pulmonary trunk.2 Of the four courses, an 
anomalous LM with septal course is the most common, 
while an anterior LM course is the least common.
While an anomalous LM with interarterial course 
is associated with myocardial ischemia or sudden 
cardiac death in young individuals,1 an aberrant LM 
with an anterior, posterior, or septal course is generally 
considered benign.3 Clinically significant symptoms 
associated with an anterior course are uncommon, but 
have been reported in two cases.4 The most common 
symptoms of this variant include angina pectoris and 
myocardial ischemia in the absence of coronary artery 
disease. 
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A Rare Case of Tumor Lysis Syndrome 
Anne Mainardi, MSIV, Daniel Okamoto, MD, Jianqing Lin, MD
inTroDucTion
Tumor lysis syndrome (TLS) is a metabolic disturbance 
caused by the destruction of rapidly dividing cancer cells 
following administration of cytotoxic chemotherapy. 
The subsequent release of intracellular material results 
in hyperuricemia, hyperkalemia, hyperphosphatemia, 
and hypocalcemia.1 The clinical presentation of TLS, 
including acute kidney injury, results from these 
electrolyte abnormalities and can be life-threatening.2 
Here we present the second reported case of TLS in a 
woman with endometrial cancer.
caSE PrESEnTaTion
A 63 year old woman with newly-diagnosed 
endometrial cancer (International Federation of 
Gynecology and Obstetrics, FIGO, stage IVB) who 
received her first dose of carboplatin and paclitaxel 
four days earlier presented to the emergency room 
with shortness of breath and lower extremity swelling. 
Her physical examination was significant for a heart 
rate of 132 beats per minute and a respiratory rate 
of 26 breaths per minute. She was noted to have a 
harsh systolic murmur loudest at the right second 
intercostal space and a mildly distended abdomen. 
Chest radiography was unremarkable. A ventilation 
perfusion scan was negative for pulmonary embolism. 
Her labs at time of admission (Table 1) were consistent 
with tumor lysis syndrome. Based on the Cairo-Bishop 
criteria (described below), the diagnosis of tumor 
lysis syndrome was made.
ouTcoME anD FollowuP
The patient received vigorous intravenous hydration 
with normal saline solution and treatment with 
intravenous rasburicase. After two doses of rasburicase 
her labs began to normalize (Table 1), and her symptoms 
dissipated. On the day of discharge all lab abnormalities 
had resolved, and the patient was discharged in stable 
condition.
Table 1. Laboratory Values 
Lab Parameter 
(normal range at TJU)
Pre- chemotherapy Admission 2 days after rasburicase
Serum potassium 
(3.5-5.0 mmol/L)
4.4 5.5 4.5
BUN 
(7-27 mg/dL)
14 68 65
Serum creatinine 
(0.7-1.4 mg/dL)
0.8 2.4 1.9
Serum phosphate 
(2.4-4.5 mg/dL)
n/a* 6.1 4.3
Serum calcium 
(8.5-10.5 mg/dL)
n/a* 8.3 8.3
Serum Urate 
(2.5-6.0 mg/dL) 
n/a* 15 5.1
*values were not measured
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associated with endometrial cancer. In this case from 
2010, a 60 year old woman with recurrent FIGO 
stage IIB endometrial cancer developed TLS four days 
after receiving carboplatin and paclitaxel. The patient 
required hemodialysis and expired despite aggressive 
management.7 
While TLS remains a rare complication of chemotherapy 
in patients with solid tumors, the clinical characteristics 
of patients at high risk for TLS should be recognized 
(Table 2).8 In 2004, Cairo and Bishop proposed a system 
for diagnosing and classifying tumor lysis syndrome. 
DiScuSSion
TLS is a rare but serious complication of cytotoxic 
chemotherapy. Malignancies with the highest risk of 
TLS are those with both high proliferative rates and 
tumor burden, particularly hematologic malignancies.3 
Solid tumors have a much lower incidence of TLS. A 
literature review found the highest incidence of TLS 
in small-cell carcinoma and breast carcinoma, with a 
few reported cases each in neuroblastoma, germ cell 
tumors, melanoma, and others.4 While a few cases of 
TLS have been reported in association with gynecologic 
cancers,5,6 there has been only one reported case 
Table 2. Clinical Characteristics of Patients at High Risk for Tumor Lysis Syndrome
Tumors with a high proliferation rate and sensitivity to cytotoxic agents
Large tumor masses
Renal insufficiency and obstructive uropathy
Elevated serum lactate dehydrogenase or uric acid level
Dehydration
TABLE 3. Cairo-Bishop definition of laboratory tumor lysis syndrome in adults.
Diagnosis requires two or more of the following abnormalities observed within three days before to seven days after 
initiation of chemotherapy:
Uric acid Greater than or equal to 8.00 mg/dL or 25% increase from baseline
Potassium Greater than or equal to 6.00 mmol/L or 25% increase from baseline
Phosphorous Greater than or equal to 4.5 mg/dL or 25% increase from baseline
Calcium Less than or equal to 7.0 mg/dL or 25% decrease from baseline
Table 4. Cairo-Bishop definition of clinical tumor lysis syndrome in adults. 
Diagnosis requires meeting criteria of laboratory tumor lysis syndrome plus one or more of the following not directly or 
probably attributable to a therapeutic agent:
1 Creatinine greater than 1.5 times upper limit of normal (our ULN = 1.4 mg/dL)
2 Cardiac arrhythmia/sudden death
3 Seizure
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Table 3 describes the laboratory definition of TLS, and 
Table 4 describes the clinical definition of TLS. Acute 
kidney injury in TLS results from the release of nucleic 
acids from lysed tumor cells, which are degraded by 
xanthine oxidase to hypoxanthine, xanthine, and uric 
acid.9 In the acidic environment that often occurs 
as a result of volume depletion, uric acid solubility 
decreases10 and crystallization occurs in the distal tubules 
and collecting ducts. This crystallization obstructs the 
tubular lumen and leads to inflammation.11 Uric acid 
may also contribute to acute kidney injury by crystal-
independent mechanisms, due to its vasoconstrictive, 
anti-angiogenic, pro-inflammatory, and pro-oxidative 
properties.12 The other features of clinical tumor lysis 
syndrome - tetany, cardiac arrhythmias, and seizures – 
also result from the metabolic derangements that 
occur when cancer cells are lysed by cytotoxic 
chemotherapy.13 The patient described here did not 
exhibit these manifestations.
The treatment of tumor lysis syndrome is mainly 
supportive and includes cardiac and electrolyte 
monitoring, correction of electrolyte abnormalities, 
intravenous fluids (isotonic saline solution at 2500-3000 
mL/m2/24 hours), and renal replacement therapy if 
indicated.14 Urinary alkalinization is controversial. The 
patient described here received four liters of normal 
saline and two doses of rasburicase. Rasburicase 
decreases uric acid levels by catalyzing the conversion 
of uric acid to allantoin, which is more soluble in 
urine.15 This is in contrast to allopurinol, a prophylactic 
medication, which competitively blocks xanthine 
oxidase, preventing the conversion of purines to uric 
acid.16,17 Once TLS is diagnosed, rasburicase is the 
appropriate therapy to eliminate the excess uric acid.13 
KEy PoinTS
Successful management and treatment of TLS is highly 
dependent on the prompt identification of clinical and 
laboratory characteristics, signs, and symptoms of 
patients at risk. The initiation of prophylactic measures, 
especially hydration and administration of allopurinol, 
and the early recognition and treatment of metabolic 
abnormalities using rasburicase can prevent the severe 
and life-threatening complications associated with TLS. 
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Recurrent Unilateral Pleural Effusion from 
Constrictive Pericarditis of Unknown Etiology 
Requiring Pericardiectomy
Aishah Ali, MD, Gina Keiffer, MD
inTroDucTion
Constrictive pericarditis is an uncommon cause 
of unilateral pleural effusion. In patient’s who have 
repeated thoracenteses with no obvious cause for 
the pleural effusion, constrictive pericarditis should be 
considered. Right and left heart catheterization is used 
to diagnosis constrictive pericarditis by measuring filling 
pressures of the heart. 
caSE rEPorT
A 52-year-old man with a history of hepatitis C, hepato-
cellular carcinoma (HCC), status post liver transplant in 
July 2013, chronic kidney disease, gastroesophageal 
reflux disease and hypothyroidism presented with 
increasing dyspnea with minimal exertion and was found 
to have recurrent pleural effusion. Patient had been 
worked up as an outpatient for recurrent pleural effusion 
but no etiology had been found. Prior thoracentesis on 
three different occasions within a month had yielded 
exudative fluid with no evidence of malignant cells. The 
effusions re-accumulated within one week on each 
occasion. The patient had previously been treated with 
diuretics without resolution of his recurrent pleural 
effusion. With worsening of his renal function, diuretics 
had recently been discontinued. The patient denied 
shortness of breath at rest, cough and chest pain as 
well as fevers and chills. He also denied orthopnea and 
paroxysmal nocturnal dyspnea. Medications included 
tacrolimus, levothyroxine, omeprazole and a daily 
multivitamin. The patient has a history of prior alcohol 
abuse and prior tobacco use (10 pack years). 
The patient’s vital signs were significant for mild 
tachypnea (20 respirations per minute) with normal 
oxygen saturation. He initially appeared healthy and 
in no acute distress. He had jugular venous distention. 
Pulmonary exam was clear on the left with decreased 
breath sounds in the right mid- and lower-lung fields. 
There was mild, bilateral lower extremity pitting edema. 
The patient’s renal function was at his baseline (creatinine 
= 1.8 mg/dL, normal range 0.7 – 1.4). Complete blood 
count identified leukopenia, mild normocytic anemia, 
and thrombocytopenia. The patient’s labs identified 
elevated pro-brain natriuretic peptide (2511 pg/mL, 
normal range <125 pg/ml) and normal hepatic function 
panel except mildly elevated total bilirubin (1.3 mg/
dL, normal range 0.1 - 0.9 mg/dl). Chest X-ray in the 
Emergency Department identified a large right pleural 
effusion, increased from a study one week prior and 
associated right basilar atelectasis as well as a small left 
pleural effusion and background pulmonary edema. 
The patient was admitted and work-up for recurrent 
unilateral pleural effusion was initiated.
DiFFErEnTial DiagnoSiS
Differential diagnosis for an exudative unilateral effusion 
includes infectious etiologies, including tuberculosis 
and parapneumonic effusion. Additionally, there was 
concern for a malignant effusion secondary to the 
patient’s history of HCC.
HoSPiTal courSE
The patient’s shortness of breath worsened over 
the first few days of hospital stay. He became more 
volume overloaded, with 2+ pitting edema in lower 
extremities and increasing ascites. He had a therapeutic 
thoracentesis every other day for three total occasions 
with a liter of pleural fluid removed each time. Pleural 
fluid labs showed an alkaline pH (7.63, normal 7.6 – 7.64), 
slightly elevated glucose (114 mg/dL, normal 75-100 
mg/dl), elevated lactate dehydrogenase (LDH) of 115 
IU/L (normal LDH is <50% of plasma), and increased 
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protein (3.5 g/dL). Serum LDH was 155 IU/L, yielding 
a pleural to serum LDH ratio of 0.7, consistent with an 
exudative pleural effusion. Cytology was negative for 
malignancy on each occasion.
The patient was scheduled for video-assisted 
thoracic surgery (VATS) for pleural biopsy and chest 
tube placement for continuous drainage of the 
pleural effusion. On pre-operative assessment, the 
cardiologist recommended a right heart catheter-
ization (RCH) to evaluate pulmonary artery pressures. 
The RCH was significant for elevated right atrial, right 
ventricular, and pulmonary capillary wedge pressures. 
A left heart catheterization (LHC) was then planned to 
further evaluate the etiology of the patient’s elevated 
right-sided pressures. Differential included left heart 
failure, constrictive pericarditis and restrictive cardiomy-
opathy. The LHC demonstrated elevated left ventricular 
end diastolic pressures with normal cardiac output. 
Hemodynamic respiratory alteration was inconclusive 
in distinguishing constrictive pericarditis from restrictive 
cardiomyopathy. An echocardiogram showed abnormal 
interventricular septal motion (“septal bounce”), findings 
consistent with both constrictive pericarditis and 
restrictive cardiomyopathy. The echocardiogram also 
showed mild pericardial thickening, making constrictive 
pericarditis the more likely diagnosis. Pericardiectomy, 
was discussed with the patient. The patient planned 
to be discharged and obtain a second opinion on 
treatment options. 
Prior to planned discharge, the patient’s status abruptly 
worsened with the development of ascites, progressive 
renal failure, and increasing shortness of breath requiring 
every other day thoracenteses. VATS at this time did 
not seem necessary as it would not treat the underlying 
condition. Because of the patient’s clinical deterioration, 
pericardiectomy was pursued. The patient tolerated 
the procedure without complications. Right heart 
filling pressures decreased almost immediately after 
the procedure. The patient’s renal function improved 
back to baseline and his right-sided pleural effusion 
did not re-accumulate. The patient was ambulatory on 
discharge. Final pathology of the pericardium showed 
chronic inflammation and fibrosis, consistent with 
constrictive pericarditis.
DiScuSSion
The majority of cases of constrictive pericarditis are 
idiopathic or viral in etiology, followed by post-cardiac 
surgery and post-mediastinal irradiation.1 Most of the 
patients present with symptoms of chronic heart failure. 
Only a minority of patients present with recurrent 
pleural effusion, and those who do typically have a 
bilateral, transudative effusion.2 That our patient had an 
unilateral, exudative pleural effusion was a red herring 
and caused significant diagnostic delay. 
Postero-anterior chest x-ray is the initial diagnostic test 
of choice for evaluation of suspected pleural effusion 
and can identify as little as 200 mL of pleural fluid. 
Bilateral pleural effusion in a clinical setting suggestive 
of transudative effusion rarely require fluid analysis and 
can typically be treated by appropriately treating the 
underlying cause. Most common causes of transudative 
pleural effusion are increased hydrostatic pressure 
secondary to cardiomyopathy or liver cirrhosis. Less 
common causes include hypoalbuminemia, nephrotic 
syndrome, hypothyroidism, and mitral stenosis. The 
most common causes of exudative pleural effusions, 
on the other hand, are tuberculosis, malignancy, and 
parapneumonic effusion. Less common causes include 
pulmonary embolism, rheumatoid arthritis, pancreatitis, 
and post-myocardial infarction. Drugs and fungal 
infections are rare causes. 
Our patient’s abnormal right and left heart catheter-
ization established diastolic heart failure as the cause of 
his pleural effusion, but the etiology of his heart failure 
was uncertain. Our differential included constrictive 
pericarditis vs. restrictive cardiomyopathy. Historically, 
clinically distinguishing these two entities has posed 
a significant challenge. Two-dimensional and Doppler 
echocardiography, pericardial visualization with CT 
scan or MRI and cardiac catheterization may be useful, 
but the diagnosis may remain equivocal after these 
tests in some patients.3 Both cause diastolic heart failure 
with abnormal ventricular filling pressures. Typical 
hemodynamic measures during cardiac catheter-
ization include early rapid filling and equalization of 
end-diastolic pressures in all four cardiac chambers, but 
these may also be present in patients with restrictive 
cardiomyopathy. Some authors have suggested that 
assessing dynamic respiratory changes that can be 
observed in patients with constrictive pericarditis during 
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KEy PoinTS
Constrictive pericarditis is an infrequent cause of 
unilateral pleural effusion. This case was notable 
because etiology of his unilateral pleural effusion was 
unclear and his clinical status deteriorated quickly 
while the workup of his effusion was being completed. 
Constrictive pericarditis and restrictive cardiomyopathy 
must be on the differential when the etiology of pleural 
effusion is unclear. Imaging can suggest constrictive 
pericarditis; however, cardiac catheterization can 
further evaluate the patient’s hemodynamics and 
strengthen the diagnosis.5 Definitive diagnosis is made 
with pericardial biopsy. The treatment for constrictive 
pericarditis is total or partial pericardiectomy.
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cardiac catheterization may help distinguish these 
patients.4 Definitive diagnosis requires pericardial or 
endomyocardial biopsy. 
Despite the difficulty, clinically distinguishing constrictive 
pericarditis and restrictive cardiomyopathy is crucial, as 
their treatment differs greatly. Removing the fibrotic 
pericardium encasing the normal myocardium, a 
procedure known as “pericardial stripping” or pericardi-
ectomy, treats constrictive pericarditis. With restrictive 
cardiomyopathy, however, the myocardium itself is 
impeding normal diastolic filling, and, thus, treatment 
is heart transplant.
Diagnostic uncertainty was a challenge for our patient. 
Our patient initially had a normal echocardiogram, but 
as his disease worsened his echocardiogram displayed 
a picture consistent with constrictive physiology, 
including mild thickening of pericardium and abnormal 
interventricular septal motion (“septal bounce”). 
Hemodynamic studies were inconclusive and the 
patient’s abrupt clinical decline forced us to proceed 
with pericardiectomy based on clinical suspicion. 
Prior to pericardiectomy, our patient was warned that 
were pericardiectomy unsuccessful, indicating either 
myocardial atrophy due to prolonged constriction or a 
true diagnosis of restrictive cardiomyopathy, he would 
require a heart transplant.
Complete pericardiectomy remains the treatment of 
choice for constrictive pericarditis, as compared to 
partial pericardiectomy, and has been associated with 
lower peri-operative mortality and improved long-term 
survival. Like our patient, most patients with constrictive 
pericarditis have significant clinical improvement 
following pericardiectomy. The peri-operative mortality 
rate of pericardiectomy is 6%, most frequently 
secondary to low-output cardiac failure. Independent 
risk factors for increased risk of late mortality include 
increased age, higher pre-operative New York Heart 
Association (NYHA) class (class III and IV) and prior 
mediastinal irradiation. Myocardial atrophy after 
prolonged constriction can cause residual heart failure 
post-operatively despite successful pericardiectomy.5
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An Unusual Atrial Mass: A Case Study
David F. Reilly, BS, Christina C. Lindenmeyer, MD
BacKgrounD
This case highlights the evolution of a broad differential 
diagnosis when presented with a rare and diagnostically 
enigmatic clinical finding. 
caSE PrESEnTaTion
A 43-year-old Puerto Rican male with a history of 
homelessness, intravenous drug abuse, and incarceration 
presented following an episode of syncope. His past 
medical history was notable for a recent diagnosis of 
granulomatous nephritis, thought to be secondary to 
isolated renal sarcoidosis. He had been treated with 
high dose prednisone and subsequently initiated on 
hemodialysis. On presentation, he complained of 
rigors, shortness of breath, cough, abdominal pain 
and coffee-ground emesis. On initial examination, 
the patient was ill-appearing, febrile, tachypneic and 
tachycardic. He was awake and oriented with no focal 
neurological deficits. 
His sepsis evaluation included computed axial 
tomography (CT) scans of his chest, abdomen and 
pelvis. Imaging was notable for para-aortic lymphade-
nopathy, diffuse micro-nodular densities throughout 
the lungs, hilar and mediastinal lymphadenopathy, and 
advanced xanthogranulomatous pyelonephritis with 
extensive calcification of the right kidney. His blood 
and urine cultures grew a resistant strain of Escherichia 
coli and he was initiated on broad antibiotic coverage, 
delivered via a central venous catheter. Further 
evaluation for endocarditis included both transthoracic 
(TTE) and transesophageal (TEE) echocardiograms, 
which identified a well-demarcated, heterogeneous 
right atrial (RA) density measuring 1.7 x 1.6 cm. He 
was initiated on full anticoagulation for this presumed 
catheter-associated right atrial thrombus. A head 
CT demonstrated an abnormal 1.2 x 3.6 cm lobular 
hyper-density in the right frontal lobe with surrounding 
edema, and multiple dispersed punctate calcified 
hyper-densities. 
Soon after presentation, the patient developed seizures 
and acute respiratory failure, necessitating intubation. His 
chest x-ray demonstrated progression of innumerable 
bilateral pulmonary micro-nodular densities. He 
underwent bronchoscopy, and pathology was notable 
for acute fibrinous and organizing pneumonia. Initial 
concentrated sputum smears were negative for 
acid-fast bacilli (AFB). He was, however, initiated on 
empiric anti-tuberculosis quadruple pharmacotherapy 
(RIPE) given his exposure risk, chronic immunocom-
promised state, and concern for miliary tuberculosis. 
He was eventually weaned from the ventilator and was 
extubated. Subsequently, a right-sided percutaneous 
nephrostomy tube was placed to relieve his obstructing 
xanthogranulomatous pyelonephritis. Cultures from 
the nephrostomy tube were notable for the growth 
of Mycobacterium Tuberculosis Complex (MTB), as 
were cultures from his bronchoscopy, confirming 
disseminated MTB. His original sputum cultures later 
grew MTB 19 days after collection.
Several weeks into his hospital stay, a lower gastro-
intestinal bleed prompted the discontinuation of his 
anticoagulation, necessitating re-evaluation of the 
right atrial mass. TTE revealed an expanded (4.2 x 
3.3 cm) multi-lobulated, heterogeneous echo-dense 
RA mass extending towards the inferior vena cava/
RA junction with new focal areas of brightness 
suggesting calcification. Hemodynamic assessment 
including orthostatics and central venous pressure 
estimation were normal. Although airborne precautions 
precluded endoscopic evaluation of the gastrointestinal 
hemorrhage, the imminent risk of the growing atrial 
mass prompted reinstitution of anticoagulation, which 
he was able to tolerate.
In the setting of disseminated MTB infection, the 
patient’s chronic steroids were slowly tapered. 
However, he quickly developed a new facial droop, 
unilateral weakness and altered mental status. It was 
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improved. He has remained hemodynamically stable, 
precluding the need for surgical intervention of his atrial 
mass. He will require monthly monitoring with TTE, a 
prolonged course of RIPE, and long-term anticoagu-
lation for management of his disseminated tuberculosis 
and undifferentiated right atrial mass. 
DiScuSSion
The constellation of findings presented in this case 
represent a broad differential diagnosis, including 
systemic sarcoidosis, lymphoproliferative disorders, 
and infections.1 Sarcoidosis and lymphoproliferative 
disorders are known to involve the lungs, kidneys, central 
nervous system, gastrointestinal tract and reticuloendo-
thelial system. However, the isolation of MTB from two 
separate sources in an immunocompromised patient at 
high risk for previous MTB exposure makes the diagnosis 
of primary or reactivation disseminated tuberculosis 
most likely.1-3 With strong clinical, microbiological 
and radiographic evidence supporting a diagnosis of 
disseminated tuberculosis, the immediate institution 
of RIPE and rapid identification and management of 
potential end-organ complications is paramount. 3
Less than 1.5% of all MTB infections disseminate lympho-
hematogenously. Most often the lungs are affected, 
but, after lymphadenopathy, the next most common 
manifestations of non-pulmonary tuberculosis include 
gastrointestinal and hepatic (80%), genitourinary (27%), 
and meningeal (20%).1,4,5 Infiltration of the myocardium 
is uncommon, and the documented incidence of 
intra-cardiac tuberculoma is rare, with a majority of 
cases diagnosed at autopsy.6
The few reported cases of cardiac tuberculoma 
diagnosed in vivo describe single or multiple well-circum-
scribed, heterogeneous masses often occupying the 
right atrial free wall.6-9 Echocardiography is often used to 
characterize size, location and echogenicity. Magnetic 
Resonance Imaging is able to provide more detail, but 
often fails to distinguish tuberculoma from thrombus 
and myxoma.7 Percutaneous biopsy under echocar-
diographic guidance provides a means of sampling 
the mass. However, identification of characteristic 
histopathological findings lacks sensitivity, and most 
reports indicate unacceptable yields for identification of 
MTB following Ziehl-Neelsen staining.6,7,9 A confirmatory 
diagnosis requires invasive removal of the mass for 
thought that his neurological change was secondary 
to tuberculous cerebritis. He was quickly re-initiated on 
high dose prednisone, and his mental status improved. 
He later developed recurrent polymicrobial bacteremia 
from his pyelonephritis and required a prolonged 
course of antibiotics. Nephrectomy was deemed to 
be prohibitively high risk in the setting of his multiple 
comorbid conditions. 
As his infections were appropriately managed, a multi-
disciplinary approach in concert with cardiology, 
infectious diseases, radiology and interventional 
radiology was undertaken to further elucidate the 
etiology of his undifferentiated atrial mass. Given his 
multiple co-morbidities, poor functional status and 
chronic immunosuppression, invasive diagnostics were 
deferred, and it was decided that he would be continued 
on empiric anticoagulation in combination with RIPE 
therapy for both thrombus and atrial tuberculoma.
DiFFErEnTial DiagnoSiS
The patient presented with a previous pathological 
diagnosis of renal-limited sarcoidosis and had been 
treated with several months of high-dose cortico-
steroids. He then developed persistent fevers, 
neurological deficits, miliary pulmonary infiltrates, 
calcified cerebral hyper-densities, presumed enteritis, 
xanthogranulomatous pyelonephritis, and an atrial 
mass. Initially, a diagnosis of systemic sarcoidosis 
remained high on the differential. Given the patient’s 
immunocompromised state, polymicrobial infections, 
and progression of systemic manifestations on cortico-
steroids, also included in the initial differential diagnosis 
were lymphoproliferative disorders, neoplasms, and 
infections (including disseminated tuberculosis). 
An intra-cardiac mass is an uncommon finding that 
carries a broad differential diagnosis, including thrombus, 
vegetative endocarditis, myxoma, myosarcoma, 
rhabdomyosarcoma, infiltrative lymphoma, secondary 
deposits and cardiac tuberculoma. 
ouTcoME anD Follow-uP
Following institution of RIPE therapy for disseminated 
tuberculosis, targeted antimicrobials for bacteremia, 
steroids for tuberculous cerebritis and empiric antico-
agulation for his atrial mass, the patient’s clinical status 
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gross histopathological diagnosis.7 Few studies have 
demonstrated successful reduction in size, and even 
complete resolution of cardiac tuberculomas following 
appropriate anti-tuberculosis pharmacotherapy alone. 
6,8 Surgical intervention is indicated if the mass results 
in clinically significant hemodynamic compromise, or 
if diagnosis remains unclear after pharmacotherapy has 
failed to demonstrate improvement by imaging.6,8,9
Given the patient’s encouraging response to 
anti-tuberculosis pharmacotherapy and anticoagu-
lation, as well as persistently stable hemodynamics, 
further diagnostics of the right atrial mass were deferred. 
The risk of interventional diagnostics were thought to 
outweigh any benefits, given that the treatment plan 
of combining anticoagulation with RIPE therapy would 
remain unchanged.
KEy PoinTS
Cardiac tuberculomas are a rare complication of 
disseminated MTB infection and should be considered 
in the differential diagnosis of an intra-cardiac mass 
in a patient with proven MTB. With strong clinical and 
radiographic evidence, and without hemodynamic 
compromise, invasive diagnostics may be deferred in 
favor of empiric medical management.
"Sunset over Naraganssett Bay, Rhode Island” 
photograph by Andrew Zabolotsky, MD
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A Case of Complete Heart Block Secondary  
to ANCA-Associated Vasculitis
Krista Lim-Hing, MD
inTroDucTion
Anti -neutrophil cy toplasmic antibody (ANCA) 
associated vasculitides are systemic autoimmune 
diseases that often present as non-specific prodromal 
symptoms such as fever, fatigue, headache, and 
weight loss.1 With modern treatment, the disease has 
changed from being universally fatal to being treatable. 
It can have a chronic relapsing and remitting course. 
Therefore, early diagnosis is necessary.2,3
caSE PrESEnTaTion
A 53-year-old male with a past medical history of 
chronic sinusitis and some epistaxis needing multiple 
courses of antibiotics and steroids, was admitted after 
being diagnosed with high-grade heart block at another 
institution. He was found to have a heart rate of 26 and 
was given a temporary pacemaker prior to the transfer. 
Subsequently, a dual-chamber pacemaker was placed. 
An echocardiogram showed mild aortic stenosis and 
regurgitation with right ventricular enlargement and an 
ejection fraction of 65%. No etiology was found for the 
heart block and work up was negative for medications, 
electrolytes, ischemia, significant structural heart disease 
or lyme disease. Pacer placement was without any 
complications. The patient was discharged home and 
did well for 10 days and then returned again to the 
emergency room with complaints of dry cough, chest 
pain, progressive shortness of breath, fatigue, and fever 
to 101.2 degrees Fahrenheit. He reported a fifteen pound 
weight loss over the past month. His family history was 
noncontributory. He worked as an auto mechanic and 
reported former cocaine use over 20 years ago. He had 
no history of tuberculosis exposure and was up to date 
on his screening colonoscopy.
Physical exam findings included mildly congested 
bilateral nares with some postnasal thick secretions. 
On careful examination, he had “saddle nose” anatomy 
that he claimed to have noticed just months prior to 
presentation. Auscultation of his lungs revealed crackles 
diffusely and posterior left lung base egophony but no 
wheezes.  The lung findings were new as compared to 
the recent admission for heart block. There was nothing 
significant on the basic laboratory tests. Chest x-ray and 
CT scan on admission revealed diffuse bilateral airspace 
opacities and nodule consolidation with mediastinal and 
right hilar adenopathy. These findings were suspicious 
for multifocal pneumonia with a separate infectious 
inflammatory process.
DiFFErEnTial DiagnoSiS
On initial presentation the differential diagnosis ranged 
from infectious to autoimmune to malignant pathology. 
There was initial concern for tuberculosis, pneumonia 
or malignancy.
HoSPiTal courSE
Blood, urine and sputum cultures didn’t identify any 
bacterial or fungal infectious etiology. AFB stains 
were negative. He underwent bronchoscopy to better 
evaluate the lung process and biopsy was performed 
revealing mild interstitial pneumonitis and intraalveolar 
red blood cells. Further in the course, patient developed 
acute kidney injury with a baseline creatinine of 0.9 mg/
dl that peaked at 2.0 mg/dl. He had no evidence of 
oliguria or dysuria. Based on his constellation of signs 
and symptoms, he underwent a work-up for vasculitides. 
This included pertinent negatives for the following lab 
studies: HIV screening, hepatitis serologies, anti-nuclear 
antibody (ANA), double stranded DNA (dsDNA), reduced 
complement levels, basement membrane antibody, 
anti-Ro/anti-La antibodies, and quantiferon assay. 
ANCA screen came back positive for p-ANCA (antimy-
eloperoxidase). A kidney biopsy revealed interstitial 
granulomatous inflammation with pauci-immune 
staining that was consistent with p-ANCA related 
glomerulonephritis. He was started on high-dose pulse 
steroids and cyclophosphamide. 
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DiScuSSion
This patient’s prodromal flu-like symptoms of fever, 
fatigue, and weight loss were classic for the initial 
vasculitis presentation.1,4 His history of chronic sinusitis 
and epistaxis that was best relieved by steroids was 
also an indication of vasculitic disease.5 The lung 
biopsy showing hemorrhagic alveolar infiltrate and 
kidney biopsy showing glomerulonephritis were 
most consistent with granulomatosis with polyangiitis 
(GPA). However, no granulomatous vasculitis or 
pulmonary capillaritis were seen in his lung biopsy. 
Large observational studies have shown that rhinology, 
pulmonary, and renal are the systems most commonly 
affected in this spectrum of diseases.6 This patient 
presented with heart block prior to the typical vasculitic 
symptoms. As no clear cut etiology was found for his 
heat block, there was a high suspicion for vasculitic 
origin of his heart block. On our review of literature, we 
found small number of case reports that reported first 
degree to complete heart block in patient’s with GPA 
and other vasculitides. 
ANCA-associated vasculitis is a subset of small-vessel 
vasculitis and includes GPA, eosinophilic granulomatosis 
with polyangiitis (EPGA), and microscopic polyangiitis 
(MPA). It is usually found in older adults but is reported 
in all ages.5 GPA specifically shows granulomatous 
inflammation of the respiratory tract and abnormal urinary 
sediment. MPA shows no granuloma formation. EPGA 
shows characteristic rhinitis, asthma, and eosinophilia.7
Cardiac complications of GPA are thought to be rare. 
While involvement of heart has been reported to be 
around 30% at autopsy in known GPA, clinical cardiac 
involvement is low.8 A recent report indicated evidence 
of cardiac involvement in 8% to 16% at the time of 
diagnosis and upto 25% during the course of the disease. 
9 The predominant cardiological involvement has been 
pericarditis (effusion), coronary arteritis and myocarditis 
(left ventricular dysfunction) on pathology.10 Valvuvar 
and conduction defects have been rarely described 
in the past. More recently, there have been increasing 
number of reports of conduction disease defects as well 
as valvular abnormalities associated with GPA. GPA can 
have pathological involvement of aortic or mitral valve, 
causing valvulitis leading to regurgitation as predominant 
valve dysfunction.9 GPA has also been associated with 
bundle branch blocks to all grades of heart block. These 
are thought to be from granulomatous inflammation 
involving the AV node or the bundle of his.11 We believe 
that our patient’s heart block was associated with GPA. 
The close time between the two diagnosis, as well as 
similar sequence of events like diagnosis of heart block 
first and then diagnosis of GPA in some other case 
reports substantiate our association. Heart block has 
been reversible with treatment of GPA with immunosup-
pression in some literature.12-14 
 The approach to treatment of ANCA associated vasculitis 
can be divided into two categories: mild disease and 
moderate to severe disease. For mild disease, with no 
evidence of glomerulonephritis or organ-threatening 
disease, a regimen of glucocorticoids in combination 
with rituximab or methotrexate should be started. If 
the disease is refractory to methotrexate treatment 
the patient should have a trial of cyclophosphamide. 
Moderate to severe disease demonstrates organ damage 
and has a less defined recommendation for treatment. 
Overall, literature supports either a cyclophosphamide or 
rituximab-based regimen in combination with glucocor-
ticoids.3 Prophylaxis against opportunistic infections 
during induction immunosuppression is also suggested. 
Our patient's heart block resolved before starting steroids, 
so it was likely a temporary block.
KEy PoinTS
ANCA-associated vasculitis can initially present with 
prodromal  flu-like symptoms and signs of inflammation. 
Thought not very common, ANCA-associated vasculitis 
can be associated with cardiac valvulopathy and 
conduction abnormalities. Patients presenting with 
heart block and recent history of or current symptoms 
of inflammatory or infectious disease, should be 
screened for GPA and vasculitides in addition to lyme 
disease and viral myocarditis work up. If caught early, 
heart block due to vasculitis is potentially reversible 
and can save a patient from unnecessary procedures. 
The management consists of immunosuppression with 
steroids and other agents. 
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Hepatitis C Therapy: Serendipitous Successes 
Apeksha Shah, MD, Jonathan Fenkel, MD
of IFN and RBV, two years earlier. He was Child-Pugh 
class A and had no evidence of liver decompensation 
on examination. His baseline HCV RNA was 1.50x106 IU/
mL. He started treatment with IFN, RBV and telaprevir. He 
experienced side effects of therapy including anorectal 
burning, constipation, fatigue, and anemia requiring 
erythropoetin injections. He also achieved rapid 
virologic response at one month into therapy. Three 
months into therapy, the patient developed an abscess 
in the right axilla, which required surgical drainage and 
an indwelling drain. Antiviral therapy was terminated at 
that time. 64 weeks after termination of treatment, the 
patient remains in SVR with no complaints. 
DiScuSSion
HCV infection is a leading cause of chronic liver disease 
worldwide.3 While many patients with HCV may have a 
normal life expectancy, about 30% progress to end-stage 
liver disease, with the complications of cirrhosis and 
hepatocellular carcinoma.1 Due to this threat of severe 
disease, much focus on developing effective therapies 
has occurred over the past ten years.2 The mainstay 
of therapy has been IFN, which is used synergistically 
with RBV, likely through multiple mechanisms of 
action.2 IFN is thought to inhibit HCV replication by 
inducing IFN-stimulated host genes that have antiviral 
functions. It also induces viral clearance, along with 
displaying biochemical and histological benefits.4 This 
combination has been used in chronic HCV infection 
with rates of SVR estimated to be 31-67% depending on 
the HCV genotype, the dosage of IFN and RBV, and the 
duration of therapy4. Newer agents have recently been 
introduced, some of which act directly on viral targets, 
and others target host proteins essential to replication. 
The most commonly used agents from 2011-2013 were 
telaprevir and boceprevir, which are inhibitors of the 
N3/4A protease. A newer once daily protease inhibitor, 
simeprevir, and the first HCV polymerase inhibitor, 
sofosbuvir, are also now available in the US and more 
inTroDucTion
Hepatitis C virus (HCV) infection is a growing epidemic 
worldwide, with about 170 million cases reported by 
2011.1 New therapies have been introduced to the 
market, but the prior mainstay of therapy involves 
pegylated interferon-alpha (IFN) along with ribavirin 
(RBV).2 Treatment with the first generation direct-acting 
antiviral agent-containing regimens consisted of at least 
24 weeks of therapy, with the goal of sustained viral 
response (SVR) – no detectable virus 24 weeks after 
treatment is completed. We report two cases in which 
therapy was terminated early due to the developed of 
severe infection, yet the patients still achieved SVR. 
caSE rEPorT 
case 1
A 54 year old woman with a benign meningioma, who 
had recently had the tumor resected, was found to 
have abnormal liver function tests. Subsequent testing 
revealed she had chronic HCV infection, genotype 
3a, with a baseline viral load of 1.57x106 IU/mL. There 
were no signs of chronic liver disease on exam, and 
an ultrasound of her abdomen revealed normal liver 
echogenicity without cirrhosis or hepatocellular 
carcinoma. 24 weeks of IFN and RBV was planned. After 
4 weeks of treatment, she had no detectable virus (rapid 
virologic response). Although she tolerated the therapy, 
after 5 weeks of initiation, the patient developed a 
wound infection at the bifrontal craniotomy surgical site 
requiring a re-operation. The treatment was terminated 
and no further treatment plans were made with an 
IFN-based regimen. 24 weeks after early termination of 
treatment, at just 5 weeks, the patient had SVR and was 
feeling well. 
case 2
A 63 year old man with history of melanoma and thyroid 
goiter, presented for retreatment of genotype 1 HCV 
with cirrhosis after relapsing to a prior 48-week course 
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had an SVR rate of 12% compared with 65% of those 
who continued treatment despite dose reduction.11 
Minimizing the duration of treatment has been 
investigated, due to the cost of therapy and side effect 
profile. In a study performed by Yu et al, it was found 
that SVR might be achieved for patients receiving a 
short treatment course of 8-16 weeks with IFN and RBV 
in genotype-2 patients with a RVR at week 4. It was also 
shown that a treatment duration of less than 20 weeks 
is likely inadequate for genotype-1 patients, before the 
advent of direct-acting antiviral agents.4 It is unusual, as 
in our case, that SVR would be obtained in such a short 
treatment period. It raises the question as to whether 
concomitant severe infection while on IFN-based 
therapy may somehow enhance treatment success – 
a question that has not been thoroughly addressed in 
the literature to date. With the advent of new IFN-free 
therapies with shorter treatment durations and improved 
side effect profiles, including combinations of protease, 
NS5A, and polymerase inhibitors, with or without RBV, 
being evaluated and introduced to the market,2 the 
study of early termination may not be relevant much 
longer, but remains an interesting medical curiosity. 
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than 15 agents are expected to be approved in the next 
four years. Future treatment looks to be IFN-free for 
most patients. 
Response to HCV therapy has traditionally been 
monitored by measuring quantitative HCV RNA by a 
sensitive assay at weeks 4, 12, and 24 followed by 4 to 
12 week intervals, at the end of treatment, and at 24 
weeks after stopping treatment rather than by a clinical 
endpoint. The goal of therapy is to obtain SVR, which 
is defined as the absence of HCV RNA from serum at 
24 weeks following discontinuation of therapy.5 The 
achievement of SVR depends on HCV genotype, the 
interferon lambda 28B region in the host, and the early 
viral kinetics of treatment.1 How quickly the virus is 
eliminated correlates with the rate of SVR 6, which is 
measured by rapid virologic response (RVR), defined as 
undetectable HCV RNA at week 4 of treatment. Patients 
who achieve an RVR may be able to shorten the 
duration of treatment but only 15-20% of persons with 
HCV genotype 1 infection and 66% with HCV genotype 
2 and 3 infections achieve an RVR.7 In our cases, both 
patients achieved RVR, predicting that their shorter 
courses may have been enough to achieve SVR.
While IFN and RBV have proven to be an effective 
combination in the treatment of HCV, they are 
associated with an often poorly tolerated side effect 
profile, leading to early termination of therapy in some 
patients. The most common adverse events include 
fatigue, headache, fevers, injection site reaction in 
greater than half of the patients, along with psychiatric 
side effects in 22-31% of patients.5,8 Lab abnormalities 
are common, with neutropenia being a frequent 
indicator for IFN dose reduction or discontinuation.1,5 
Despite discontinuation of IFN being common in 
clinical practice for this reason, it has been shown that 
IFN-induced neutropenia does not necessarily predict 
the incidence of serious infection.5,9 In our cases, IFN 
is likely implicated in increasing the patients’ risk of 
infection
Typically early termination of therapy results in reduced 
efficacy of treatment, measured by rates of SVR. To 
achieve full efficacy, patients are expected to undergo 
greater than 80% of prescribed duration of treatment.10 
Patients who discontinued treatment prematurely 
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A Case of Septic Portal Vein Thrombosis 
(Pylephlebitis)
Erin Carnish, MD, Andrew Garrett, MD, Mary Slome, MS I
inTroDucTion
Pylephlebitis, defined as suppurative thrombosis of the 
portal vein often associated with bacteremia, is a rare 
and serious complication of intra-abdominal infections. 
Prior to antibiotics, the mortality rate of this disease 
approached 100%.1 The veins adjacent to the infection 
are the first to be involved, with later spread to the portal 
vein and possibly the mesenteric and splenic veins.2-3 
Extension into the mesenteric veins can lead to bowel 
necrosis and increased morbidity and mortality.2-4
caSE PrESEnTaTion
A 63-year old male with a history of hypertension 
presented to the emergency department with one 
week of progressively worsening malaise, chills, 
severe fatigue, and right upper quadrant abdominal 
pain. He was tachycardic with a heart rate of 120 and 
hypotensive to 70/30 mm Hg. Exam revealed a mildly 
distended abdomen with tenderness to palpation in 
the right upper quadrant and right lower quadrant. 
Laboratory studies were significant for a leukocytosis 
with bandemia and an elevation of the total bilirubin 
and alkaline phosphatase. Abdominal CT scan showed 
mucosal thickening involving the rectosigmoid colon. 
Nodular rounded lesions containing bubbles of air, 
concerning for multiple abscesses, ran the length of the 
recto-sigmoid colon and extended into the mesentery. A 
thrombus was noted in the main portal vein and superior 
mesenteric vein. There was heterogeneity in the left 
hepatic lobe consistent with multiple hepatic abscesses. 
Of note, the patient had a recent colonoscopy showing 
multiple sigmoid diverticulae. He was started on broad-
spectrum antibiotics with vancomycin and piperacillin-
tazobactam. He briefly required vasopressor support. 
A heparin drip was also started to manage the portal 
vein and superior mesenteric vein thrombosis. Blood 
cultures eventually grew group C streptococcus, and 
vancomycin was discontinued per the susceptibility 
pattern. The patient was treated in the hospital for 14 
days and was discharged on oral amoxicillin-clavulanic 
acid for 14 additional days. During his stay, the patient 
was bridged to warfarin with a goal INR of 2-3. 
DiFFErEnTial DiagnoSiS 
Upon presentation, the patient met severe sepsis 
criteria and the focus was on resuscitation. The initial 
radiology report was misinterpreted as concerning for 
sigmoid cancer with hepatic metastasis, though the 
portal vein thrombosis was correctly identified upon 
re-examination with the staff radiologist. 
ouTcoME anD Follow-uP 
Despite the initial delay in diagnosis, the patient was 
still treated appropriately given his presentation. Surgery 
was consulted; however, since there were multiple 
small abscesses and no single large area to drain, 
it was decided to repeat imaging after two weeks of 
antibiotic treatment. On the repeat CT, the abscesses 
had resolved, but the portal vein thrombosis persisted. 
The patient showed great improvement over his 
hospital course, and was doing well at his one month 
follow-up with his primary care doctor. He was treated 
with warfarin for a six month course. 
DiScuSSion 
The most common presentation of pylephlebitis is 
fever and abdominal pain.4 Laboratory abnormalities 
generally include leukocytosis with a left shift and 
elevations in alkaline phosphatase5,6 Our patient fit 
these criteria. 
Infections such as appendicitis and diverticulitis are the 
most frequent predisposing conditions to pylephlebitis, 
though other intra-abdominal infections have also been 
implicated 1,7
Blood cultures are positive in 23-88% of patients.1-4  
When positive, organisms are usually bowel flora with 
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Bacteroides fragilis and Escherichia coli being the most 
common.2-4 This patient grew group C streptococcus, 
which is somewhat less common, and his source was 
diverticulitis. The diagnosis depends on identifying an 
abdominal source of infection with an accompanying 
portal vein thrombus8-11 CT is most useful in both 
respects.5,8,9 Much of the increase in incidence of this 
disease can likely be attributed to the more prevalent 
use of CT.8-12
Once a diagnosis is made, the patient should be started 
on parenteral antibiotics, usually a third generation 
cephalosporin, a fluoroquinoline plus metronidazole, 
an extended spectrum penicillin or carbapenem 
for four to six weeks.1,13 Once clinical improvement 
is observed, the patient can be transitioned to oral 
antibiotics. Usually, the recommended oral regimen is 
metronidazole plus a flurorquinolone;13 however, under 
the guidance of an infectious disease specialist and 
the culture sensitivities, this patient was discharged on 
amoxicillin-clavulanic acid. Sometimes the infectious 
source may need drainage, but otherwise surgical 
intervention is not indicated for this condition.14 There is 
no substantial evidence based medicine on the use of 
anticoagulation.1,3,13 
Limited data shows that anticoagulation may have a role 
in the case of mesenteric vein thrombosis to prevent 
bowel ischemia.15 Since this patient had SMV thrombosis, 
the decision was made to anticoagulate. While there is 
little data to support the use of anticoagulation, these are 
situations in which it could potentially decrease morbitity 
and mortality on a case-by case basis. 
KEy PoinTS 
The mortality of pylephlebitis is estimated to be 11-32%.1,3,5 
Prompt diagnosis and treatment are necessary for a 
good outcome. This diagnosis should be considered 
in all patients with abdominal pain and fever who are 
found on CT to have an intra-abdominal infection with 
a portal vein thrombus. Draw blood cultures and treat 
with antibiotics for 4-6 weeks.9
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A Case of Fanconi’s Syndrome  
in a Patient with HIV
Mariam Kabir MD, PhD, Christopher Miller MD, Rakesh Gulati, MD, MRCP,  
William R. Short MD, MPH
inTroDucTion
Tenofovir disoproxil fumarate (TDF) is a nucleotide 
analogue reverse transcriptase inhibitor (NtRTI), which 
blocks reverse transcriptase, an enzyme found in HIV. 
Since its approval for use in HIV by the FDA in 2001, 
it has contributed to effective treatment in numerous 
patients. The most common side effects include 
nausea, vomiting, diarrhea, asthenia, abdominal pain 
and hepatotoxicity. A less common side effect is 
nephrotoxicity leading to Fanconi’s syndrome. Here is 
an interesting case of Fanconi’s Syndrome caused by 
Tenofovir.
caSE
A 50-year-old Caucasian female with a past medical 
history of HIV and Hepatitis C presented to the 
Emergency Department with hypokalemia and acute 
renal failure. She had been diagnosed with HIV in 2003 
and was being managed on co-formulated Truvada 
(Emtracitabine/Tenofovir) and Efavirenz since 2008. 
She was previously on Lamivudine/Zidovudine and 
Efavirenz, which were discontinued due to side effects. 
Over the past month, the patient was noted to have 
hypokalemia and worsening serum creatinine (sCr), 
which was being treated with potassium supplements 
and avoidance of NSAIDs. On presentation she denied 
any diuretic use, nausea, vomiting, diarrhea, weakness, 
fatigue, paralysis, palpitations, syncope, lighthead-
edness or chest pain.
The patient’s HIV was under good control (last CD4 
count of 1400 cells/mm3 and viral load undetectable 
at <20 copies/ml), and her viral load for hepatitis C was 
negligible (HCV RNA quantitative real time PCR <43 IU/
ml). She did not have any history of seizure disorder, 
refractory migraine or use of drugs such as zonisamide 
or carbonic anhydrase inhibitors. Pertinent medications 
included Truvada 1 Tablet every 48 hours and Efavirenz 
600 mg at bedtime. She had no drug allergies. Social 
history was only positive for 1 pack per day of cigarette 
use for many years.
On physical exam the patient was afebrile and her vital 
signs were stable. She appeared to be in no apparent 
distress. She was alert and oriented to time, place and 
self. She did not have any scleral icterus or thrush in 
her throat. She had moist mucous membranes. Her 
pulmonary, cardiovascular, abdominal and neurological 
exams were normal. She did not have any costrover-
tebral angle tenderness. She also had no pedal edema.
Her laboratory data were as follows: sodium 135 mmol/L 
(normal 135-146mmol/L), potassium 1.9 mmol/L 
(normal 3.5-5mmol/L), chloride 97 mmol/L (89-109 
mmol/L), bicarbonate 22 mmol/L (24-32 mmol/L), BUN 
20 mg/dL (normal 7-26 mg/dL), creatinine1.7 mg/dL 
(0.7-1.4 mg/dL), anion gap 16 mmol/L (4-16 mmol/L), 
magnesium 1.9 mEq/L (1.3-2.1 mEq/L), phosphate 2 
mg/dL (2.4-4.5 mg/dL)(low). Urinalysis showed yellow 
urine with a pH of 7.0, 1+ Glucose, 1+ protein, urine 
potassium 13 mmol/L, urine osmolality 211 mmol/L, 
serum osmolality 293 mmol/L. Serum creatinine and 
potassium in 2008 were 0.8 mg/dL and 3.6 mmol/L 
respectively, and 1mg/dL and 3.5 mmol/L six months 
ago. Renal ultrasound showed mildly echogenic 
kidneys suggesting renal parenchymal disease.
DiFFErEnTial DiagnoSiS  
anD HoSPiTal courSE
Given her glycosuria, proteinuria, hypophosphatemia 
in addition to hypokalemia and acute renal failure, a 
diagnosis of renal tubular acidosis type 2 and Fanconi’s 
Syndrome was made. The etiology of this was thought 
to be her Tenofovir use (part of the Truvada combo); 
she had been receiving this for the past 5 years. Based 
on our consulting nephrologists recommendations, her 
Truvada was discontinued, her potassium was repleted 
with both intravenous and oral supplements, and her 
63
et al.: Download entire issue of The Medicine Forum, Volume 15, 2013-2014
Published by Jefferson Digital Commons, 2015
62   |  The Medicine Forum     5
renal function improved with intravenous hydration. At 
the time of discharge her Creatinine was 1.1 mg/dL and 
her potassium was 2.8 mmol/L. She was discharged 
with oral potassium supplementation and appropriate 
follow up with her infectious disease doctor.
DiScuSSion 
Tenofovir is available in combination with Emtricitabine 
in a product with the brand name Truvada. It is also 
available in a single tablet regimen, Atripla, which 
contains Tenofovir, Emtricitabine and Efavirenz. 
Tenofovir is the only NtRTI approved for use in HIV.1 It is 
also approved for the treatment of chronic hepatitis B 
and as pre-exposure prophylaxis against HIV infection.1 
Tenofovir has been deemed a suitable NtRTI secondary 
to less adverse effects on blood lipids and less 
mitochondiral toxicity. It was also found to have less 
renal toxicity in early randomized clinical trials.2 Although 
initially there were concerns given Tenofovir’s molecular/
structural similarity to other nucleotide analogs Adefovir 
and Cidofovir, which cause proximal tubulopathy by 
decreasing mitochondrial DNA replication (inhibits 
mtDNA polymerase), it was found that mtDNA depletion 
was negligible with Tenofovir.3 However in other studies, 
Tenofovir has been shown to be nephrotoxic to proximal 
tubular cells.4 The discrepancy is thought to be secondary 
to the strict inclusion and exclusion criteria applied in the 
clinical trials.4
Nephrotoxicity from Tenofovir can result in proximal 
tubular dysfunction with normal renal function, or with 
acute or chronic renal failure. The renal failure can 
happen months to years after starting the drug. The 
major renal biopsy finding is proximal tubular injury, 
ranging from mild and localized to diffuse and severe. 
This is associated with varying degrees of chronic 
tubulointerstitial scarring (i.e., tubular atrophy and 
interstitial fibrosis).5
The proximal tubulopathy results in Fanconi’s syndrome, 
either partial or complete.6 Complete Fanconi’s 
syndrome consists of renal tubular acidosis, glycosuria 
with hypophosphatemia, aminoaciduria, hypouricemia 
and tubular proteinuria. Renal function decline may 
follow tubular dysfunction.7 B2-microglobinuira is 
prevalent. 8 Patients may have osteomalacia secondary 
to phosphate wasting and calcitriol deficiency, since 
calcitriol is absorbed in the mitochondria of proximal 
tubules.7,9 Our patient in the above-mentioned case had 
most of these findings.
The incidence and prevalence of Tenofovir toxicity 
is varied. A study conducted in 2006 by a Spanish 
medical group found that 22% of tenofovir-treated 
patients had tubular dysfunction as opposed to 12% of 
naive HIV patients and 6% of HAART-treated patients. 
A retrospective study of HIV-infected patients on 
Tenofovir identified 1% whose sCr increased.10 
Thus, in order to manage patients with HIV on 
Tenofovir, one must be able to figure out who is at risk 
of nephrotoxicity. Postmarketing clinical data analysis 
showed that advanced age, low body weight, higher 
serum creatinine levels before starting Tenofovir 
treatment, comorbidities (diabetes, hypertension, HCV 
coinfection), concomitant nephrotoxic medications, 
advanced HIV infection (low CD4 counts, AIDS), and 
male sex were risk factors for Tenofovir-induced GFR 
reduction.2,10,11
FuTurE DirEcTionS 
Tenofovir alafenamide (TAF) is a pro-drug of Tenofovir 
and is currently in Phase III clinical trials.12 Compared to 
Tenofovir, TAF has increased HIV-1 activity, increased 
intracellular Tenofovir diphosphate levels by 7 fold, 
decreased circulating plasma Tenofovir levels by 90%, 
which results in lower levels of Tenofovir in kidney 
and bone tissue. This decrease will hopefully cause 
less renal toxicity as well as decreased bone mineral 
toxicity. In a recent phase 2 randomized, placebo-
controlled trial, treatment naive HIV-1 infected 
individuals were randomized 2:1 to receive Elvitegravir/
Cobicistat/Emtricitabine/TAF or Elvitegravir/Cobicistat/
Emtricitabine/Tenofovir. In the 24 week analysis, those 
receiving the compound with TAF had high levels of 
virologic suppression as well as a significantly smaller 
increase in serum creatinine and smaller decreases in 
bone mineral density of the hip and spine. 
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KEy PoinTS
Tenofovir is a widely used antiretroviral therapy, which, 
unfortunately, can cause RTA type 2 and renal failure. 
Although our patient had to stop an effective antiret-
roviral medication secondary to its side-effect of RTA 
type 2 Fanconi’s syndrome, she may still be able to use 
it in the near future if TAF gets approved.
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"Opposites Attract, Cape May, NJ" 
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A Case of Body Packing:  
Internal Smuggling of Illicit Drugs
Michael A. Valentino, MD, PhD
The patient is a 27-year old Hispanic female who 
was brought to the ER from the airport by the Drug 
Enforcement Agency (DEA) on suspicion of “body 
packing” (illicit drug smuggling via ingestion). An 
abdominal X-ray (Figures 1a,b) was obtained in 
the ER which showed multiple radiopaque foreign 
bodies which were uniform in size measuring 5 
cm x 2 cm throughout her colon. The patient then 
admitted to ingesting numerous heroin pellets. She 
subsequently had a CT Abdomen/Pelvis performed 
(Figure 2) which again showed numerous tubular 
radiopaque foreign bodies throughout the gastro-
intestinal tract. She was admitted to the medical 
intensive care unit (MICU) under police escort. 
She was treated with oral laxatives to accelerate 
passage of the pellets, and she was monitored for 
signs of opiate intoxication due to pellet rupture. 
Surgery was consulted in the event of pellet 
rupture and resultant drug toxicity uncontrolled 
with pharmacologic therapy as well other potential 
complications including intestinal obstruction and/
or perforation. She had serial abdominal x-rays 
performed to monitor for passage of all of the 
heroin pellets. All heroin pellets were collected by 
the DEA as evidence. During her hospitalization, 
the patient was able to pass all of the heroin pellets 
without any adverse events and was discharged 
into police custody.
Figure 1. (a) Admission abdominal 
X-ray. (b) Admission abdominal 
X-ray with pellets highlighted.
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Figure 2. Admission CT Abdomen/Pelvis
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Technique for Safe Placement of a  
Dobhoff Tube without a Cortrak® Machine
Jon Chao, MD, Jennifer Alloo Hong, MD
A 58 year old female with a history of end stage renal 
disease on hemodialysis, insulin dependent diabetes 
mellitus, ischemic cardiomyopathy, and adrenal 
insufficiency, presented from home with altered mental 
status and hypotension. She developed refractory 
hypotension requiring vasopressors and was admitted 
to the medical ICU for management of septic shock 
due to bacterial peritonitis. She was intubated and 
had an oro-gastric tube placed for enteral nutrition. 
However, significantly elevated gastric residuals 
developed secondary to delayed gastric emptying. We 
decided to place a post-pyloric Dobhoff tube as an 
alternative gastric access to continue enteral feeding. 
Since a Cortrak machine (an electromagnetic-guided 
enteral access system) was unavailable, we used a 
two-step approach with a portable chest x-ray to 
assess accurate and safe placement. 
We followed the two-step bedside approach that 
was first described in 1989.1 First, we advanced the 
tube to 30 centimeters and took a chest x-ray. As 
seen in Figure 1, the tip of the Dobhoff tube is in 
the left mainstem bronchus. If we had continued 
to advance the tube, we would have risked 
causing a pneumothorax. The tube was removed 
and re-advanced. Figure 2 shows the tube well 
positioned in the esophagus. Finally, the Dobhoff 
tube is completely advanced. Figure 3 shows the tip 
of the tube beyond the pylorus. 
In patients suffering from critical illness who require 
intubation, enteral feeding is preferred. However, 
some patients develop high gastric residuals limiting 
feeding via oro- or naso-gastric tube. A post pyloric 
Dobhoff tube is an excellent alternative, although it 
can carry a serious risk of pneumothorax if placed 
blindly. When a Cortrak machine is not available, a 
two step technique using a chest x-ray to confirm 
placement in the esophagus and then through 
the pylorus is an effective way to prevent serious 
complications.2,3
rEFErEncES
1. Roubenoff R, Ravich WJ. Pneumothorax due to nasogastric 
feeding tubes. report of four cases, review of the literature, and 
recommendations for prevention. Arch Intern Med. 1989 Jan; 
149(1): 184-8.
2. Krenitsky J. Blind bedside placement of feeding tubes: 
Treatment or threat? Practical Gastroenterology. 2011: 32.
3. Marderstein EL, Simmons RL, Ochoa JB. Patient safety: Effect 
of institutional protocols on adverse events related to feeding 
tube placement in the critically ill. J Am Coll Surg. 2004 Jul; 
199(1): 39,47; discussion 47-50.
Figure 1: Dobhoff in left mainstem bronchus
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Figure 2: Dobhoff in the esophagus Figure 3: Dobhoff in post pyloric region
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TB, or not TB? 
Michael A. Valentino, MD, PhD
The patient is a 43-year-old African American male with 
a past medical history of hypertension, hyperlipidemia, 
and chronic low back pain who presented to the ER 
for worsening dyspnea and a 30-lb weight loss over 
the past 3 months. He also reported a nonproductive 
cough over this period of time as well as an eruption 
of small ~1cm flesh-colored nodules on his extremities 
and trunk. He denied any fevers, chills, or night sweats. 
In the ER, he had a chest x-ray performed (Figure 1) 
which showed diffuse centrilobular nodules visualized 
throughout the lung fields in a miliary pattern. He 
subsequently had a CT Thorax (Figure 2) performed 
which showed innumerable miliary nodules and 
extensive mediastinal and hilar lymphadenopathy. 
There was suspicion for miliary tuberculosis (TB), and 
the patient was admitted and placed on airborne 
precautions. He was also found to be hypercalcemic 
with calcium of 11.9 mg/dL (normal range 8.5-10.2 mg/
dL) on admission, which improved with IV fluids. 
The patient was incarcerated over 10 years ago but 
had no other risk factors for tuberculosis: no travel 
to endemic areas, no history of homelessness, no 
substance abuse, and no known exposure to an 
individual with TB. Consultation by Infectious Disease, 
Pulmonary, and Dermatology was requested. The 
differential diagnosis included: TB, disseminated fungal 
infection, and sarcoidosis. A Quantiferon TB Gold test 
and three daily acid-fast bacilli sputum cultures were 
negative. He also had negative tests for cryptococcal 
antigen, histoplasma antigen, and blastomyces 
antibody. He did, however, have an elevated serum 
level of angiotensin-converting enzyme at 440 U/L 
(normal range 9-67 U/L). Dermatologist biopsied one 
of the patient’s cutaneous nodules, and the pathology 
revealed sarcoidal granulomatous dermatitis. Thus, the 
patient was diagnosed with disseminated sarcoidosis 
and initiated on steroids. The patient’s hypercalcemia 
was also due to sarcoidosis, as he had a low intact 
parathyroid hormone level and an elevated calcitriol Figure 2: Admission CT Thorax. 
Figure 1: Admission chest X-ray
level consistent with hypercalcemia of granulomatous 
disease. With treatment with steroids, the patient’s 
dyspnea improved. He was discharged on oral 
prednisone and recommended to follow-up with 
Pulmonary. 
70
The Medicine Forum, Vol. 15 [2015], Art. 29
http://jdc.jefferson.edu/tmf/vol15/iss1/29
 The Medicine Forum  |   69 5
A 20-year-old man presented with a non-healing ulcer 
on the dorsum of the left foot that initially appeared 
after the patient fell and hit his left foot on the edge 
of a door. An ulcer had formed and grown in size over 
the past several weeks after repeated physical insults 
and despite home wound care, as seen in Figure 1. 
Additionally, the patient had a non-healing ulcer inferior 
to his left knee. He had a notable past medical history 
of acute myelogenous leukemia (AML) in remission 
after a haploidentical stem cell transplant, uncontrolled 
diabetes type 1, and graft-versus-host disease of the 
skin. Both wounds showed no signs of osteomyelitis or 
cellulitis on MRI.
The patient’s ulcers most closely resembled pyoderma 
gangrenosum (PG), and his history was consistent with 
the pathergy associated with this disease. Pathergy is 
defined as the evidence of new skin lesions arising at 
sites of intradermal trauma due to an inflammatory 
response mediated largely by neutrophils.1 Pathergy 
is also seen in bowel associated dermatosis-arthritis 
syndrome, Behcet’s disease, and rheumatoid arthritis. 
PG occurs most frequently in the lower extremities 
and can be divided into five subgroups: classic, 
bullous, pustular, vegetative, and peristomal types.2 
Lesions usually start as tender nodules, plaques, or 
sterile pustules that become larger with trauma and 
debridement. Over several days to a week, the lesion 
often enlarges into a sharply demarcated ulcer with 
violaceous borders and a zone of erythema. PG lesions 
are extremely painful. They are thought to arise from 
loss of innate immune regulation and altered neutrophil 
chemotaxis.2 AML is the most common hematologic 
malignancy that underlies PG, with the bullous subtype 
of PG being the predominant type found in these cases. 
PG lesion development foreshadows a poor prognosis 
in AML, and its presence in myelodysplastic syndromes 
may herald a malignant transformation.1 Chronic and 
atypical cases have a higher association with underlying 
AML and myelodysplastic syndromes than typical cases.
PG is treated with anti-inflammatory agents such as 
steroids and tumor necrosis factor-alpha inhibitors. If PG 
appears as a dermatologic manifestation of a systemic 
disease, treating the systemic disease is necessary.3
rEFErEncES
1. Cohen PR. Neutrophilic dermatoses: A review of current treatment 
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2. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma 
gangrenosum: A review and update on new therapies. J Am Acad 
Dermatol. 2010 Apr; 62(4): 646-54.
3. Kroshinsky D, Hoang MP, Hasserjian RP. Case records of the 
massachusetts general hospital. case 1-2012. an 82-year-old man 
with persistent ulcers on the hands. N Engl J Med. 2012 Jan 12; 
366(2): 166-74.
Pyoderma Gangrenosum Associated with  
Acute Myelogenous Leukemia
Lekha Mikkilineni MD, Aishah Ali MD
Figure 1: Pyoderma gangrenosum of left foot 
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Swyer-James-McLeod Syndrome
Esther Molnar, MD, Arun Matthew, MD
Admission chest x-ray of an 81 year-old man admitted 
to the hospital for atrial fibrillation with rapid ventricular 
response is shown in Figure 1. The chest x-ray shows 
a unilateral hyperlucent lung, with paucity of peripheral 
vessels and decreased lung volume. Differential 
diagnosis for unilateral hyperlucent lung includes 
Swyer-James-McLeod syndrome (SJMS), centrilobular 
emphysema, allergic bronchopulmonary aspergillosis, 
congenital lobar over inflation, bronchial atresia and 
congenital interruption of pulmonary artery.1 High 
resolution CT imaging confirmed the diagnosis of SJMS 
in this patient. 
SJMS is a manifestation of post-infectious obliterative 
bronchiolitis. SJMS was first described in 1953 as 
a unilateral hyperlucent, hypovascular lung with a 
small ipsilateral hilum. Bronchiectasis, bronchial wall 
thickening and small pulmonary arteries are commonly 
associated findings. SJMS is thought to occur from 
severe post-infectious bronchiolitis occurring at less 
than eight years of age. The damage to the airways in 
early childhood impairs normal development of the 
alveolar ducts and leads to diminished arterial flow 
and hypoplastic pulmonary vasculature. Terminal air 
sacs distal to areas of bronchiolar obstruction become 
hyperinflated and alveoli are overdistended, adding to 
resistance of blood flow and giving the appearance of 
radiographic hyperlucency. The most common etiology 
of this phenomenon is adenovirus infection, but other 
infectious causes include paramyxovirus, Bordetella 
pertussis, mycobacterium tuberculosis, mycoplasma 
pneumoniae, influenza A or respiratory syncytial virus 
infections. The prevalence of SJMS has been reported 
as less than 0.01% in the general population.2,3
To make the diagnosis of SJMS, available modalities 
include ventilation-perfusion scintigraphy (V/Q scan) 
and CT imaging. V/Q scanning supports the diagnosis 
with matched ventilation/perfusion defects.4 High 
resolution CT (HRCT) during forced expiration is 
useful in demonstrating air trapping. The appearance 
of the lung on HRCT expiration with mosaic pattern 
attenuation and lack of change in volume with 
expiration is essential in making the diagnosis. HRCT 
is also useful in ruling out other potential causes of 
unilateral hyperlucent lung, such as bronchial atresia.5,6
SJMS is most commonly diagnosed by the fourth 
decade of life, usually as an incidental finding. 
Symptoms tend to be widely varied, ranging from 
completely asymptomatic patients to those with 
wheezing, coughing, hemoptysis, dyspnea on 
exertion, and recurrent bronchopulmonary infections. 
Management of SJMS includes early treatment 
of infections and influenza and pneumococcal 
vaccination. Bronchodilators may be helpful to patients 
demonstrating obstructive defects on spirometry. 
For severe cases with recurrent bronchopulmonary 
infections, lobectomy or pneumonectomy is helpful.2
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Figure 1: Admission chest X-ray
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As an intern, I thought of myself as the member of 
the team who gets the things done. I took pride in 
prioritizing my long list of tasks and efficiently working 
through each item. I spent most of my time at the 
computer, on the phone, in front of the chart, or in a 
consultant’s office. My time with patients was so limited 
that I grew more comfortable thinking about their 
medical problems away from their bedside.
At the end of my intern year, one of my patients in the 
cardio-vascular intensive care unit, developed atrial 
fibrillation with a rapid ventricular rate, during morning 
pre-rounds. Thankfully, my resident was there to help 
me think through what to do, since I was nervous about 
evaluating tachyarrhythmias. We started the treatment 
and I walked away to review the labs and telemetry. My 
resident called out, “Where is Jennifer? She should stay 
and see this.” I walked back to the room with some 
hesitation as I was worried there was something wrong. 
Indeed, we had to adjust our treatment, and with the 
change I stayed to watch the response. Throughout 
the experience, the patient laid quietly looking to us 
for reassurance, which we gave as we quickly titrated 
his medication, and controlled his tachycardia. In this 
moment at the bedside, after I had pulled myself away 
from the gripping rhythm of completing tasks for 
rounds, I realized the necessity of seeing the impact 
of my treatment as it was happening. Beyond this, I 
experienced the power of staying with my patient to 
reassure him. I realized that he relied on me and that he 
needed me to be there with him.
It is shocking when one moment seems to change your 
life forever. I have been there when a patient receives a 
new diagnosis and in that moment his life is completely 
different. Similarly, there have been moments when my 
patient’s experience redefines how I act as a physician.
This past summer I took care of a middle aged gentleman 
at the peak of his life who had a devastating bladder 
cancer. In addition to our medical therapy he required 
multiple urologic procedures to lighten the burden the 
tumor had on his body. After one of these procedures 
he grew delirious and combative. I arrived at the bedside 
and starting working through my differential diagnosis. 
His wife was grasping his hand while desperately trying 
to reorient his wandering mind. I thought to myself, 
“Ok, let me work through my mnemonic GO TIMES: 
glucose, oxygen, toxins, infection, metabolic causes, 
endocrine causes, and stroke or seizure.” At the end 
of my work up I was left with a medication reaction 
from benzodiazepines and hypoxia. I remained at his 
bedside throughout the work up and explained what I 
was thinking and doing to his wife who worked with me 
to keep reorienting him. When I left late that evening he 
was calm, still mildly confused, but better. We were all 
feeling better and calmer.
After a long three weeks of treatment it was finally time 
for him to leave the hospital. At the end of our last 
conversation, he asked me if he could give me a hug. 
His wife smiled, and I said, “Sure.” He hugged me and 
said, “You saved me.” 
I didn’t save him from his cancer. He died just one month 
later. Since I wasn’t able to save his life, it was hard for 
me to understand why he would say such powerful 
words to me. I had stayed close by his bedside when 
he needed help with his pain, delirium or anxiety. As I 
eased his suffering, he grew to trust me and rely on me. 
I felt like I was solving small problems by staying with 
him to make sure his pain, anxiety, and delirium were 
treated well. These problems seemed insignificant, 
even trivial, in the shadow of his cancer. In the end they 
weren’t insignificant at all.
It is sometimes easy to forget that my routine work up 
of common problems can have a profound effect on 
my patient. Whether I realize it or not, I can change a 
life by staying by the bedside to see how my patient 
responds to what I prescribe or to just talk about what 
is happening in his body that’s out of his control. In 
the process of the struggle with disease my patient 
changes me into a deeply caring physician with the 
power to save a life in ways big and small.
Stay
Jennifer Alloo Hong, MD
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